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Summary 
Rhabdomyosarcoma (RMS) is a highly malignant soft tissue sarcoma which 
commonly occurs in childhood and is associated with the skeletal muscle lineage. 
Two major subtypes can be determined according to histological features; alveolar 
RMS (aRMS) and embryonal RMS (eRMS). Patients with aRMS in general have a 
poorer prognosis than patients with eRMS. Molecular characteristics of aRMS tumors 
are chromosomal translocations. The most common translocation found in aRMS 
results in expression of the oncogenic PAX3/FOXO1 fusion transcription factor. This 
fusion protein seems to be the underlying aberration leading to disease development. 
Further, aRMS cells depend on PAX3/FOXO1 expression for survival. Therefore, this 
fusion protein represents an interesting target for therapy. Since it is not possible to 
inhibit PAX3/FOXO1 directly with small molecules, other strategies for targeted 
therapy are needed. Previous studies revealed that transcriptional activity of 
PAX3/FOXO1 is regulated by phosphorylation and identified PLK1 as potential 
upstream kinase. In this work I show that downregulation of PLK1 leads to reduced 
transcriptional activity of PAX3/FOXO1. This effect most probably involves a 
mechanism, by which PAX3/FOXO1 is stabilized through PLK1 mediated 
phosphorylation. Further I identified possible PLK1 phosphorylation sites within 
PAX3/FOXO1 in vitro. Site directed mutagenesis of these sites was performed. 
Alanine phosphomutants were tested in regard to their stability compared to 
PAX3/FOXO1 wild type using cycloheximide treatment of transfected RD cells (an 
eRMS cell line). I identified that inhibition of phosphorylation at S503 results in 
decreased protein stability of PAX3/FOXO1. These findings provide a mechanism, by 
which PLK1 regulates the transcriptional activity of PAX3/FOXO1. Additionally I 
found that retroviral transduction of RD or hMSC cells with the fusion transcription 
factor resulted in PAX3/FOXO1 target gene expression, suggesting that this might be 
a useful tool to test transcriptional activity of PAX3/FOXO1 phosphomutants.  
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1 INTRODUCTION 
1.1 Cancer 
Cancer is one of the leading causes of death and its incidence has significantly 
increased during the last century because of aging, growth of the world population, 
and an increase of cancer causing behavior [1]. Cancers can occur anywhere in the 
body [2]. In men, the most common cancer is prostate cancer followed by lung and 
colon cancer. In women, breast cancer is the most diagnosed type. Lung cancer has 
the highest mortality rate in general [3] (Fig. 1). Cancer is a heterogeneous group of 
diseases characterized by uncontrolled cell growth of abnormal cells, which in most 
cases form a tumor. Additionally, these cells possess the ability to invade other 
tissues.  
 
Figure 1: Estimated cancer-caused deaths by Sex, 2010 in the Uited states [3] 
 
1.1.1 Hallmarks 
Cancer cells arise because of alterations in their DNA. These range from point 
mutations, insertions and deletions to chromosomal translocations and 
amplifications. These alterations exert a pathologic effect by causing loss of function 
of tumor suppressor genes or gain of function of oncogenes. Under normal 
circumstances, these damages can either be repaired or the cell undergoes 
apoptosis. Most DNA damages are generated by mistake during normal cell division 
or by environmental factors (age, carcinogens, viruses). In fewer cases, DNA 
damage can also be inherited [2]. Carcinogenesis is a multistep process during which 
normal cells are transformed into malignant and invasive phenotypes. Because of 
genetic instability over several rounds of cell divisions, cancer cells can accumulate 
properties allowing them to resist cell death, sustain proliferative signaling, resist 
growth suppression, activate invasion and metastasis, aquire replicative immortality 
and induce angiogenesis. These are the so called hallmarks of cancer, which are 
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responsible for the transformation of normal cells into cancer cells. Recently, new 
hallmarks were defined including the deregulation of cellular energetics, escaping 
from immune response and tumor promoting inflammation (Fig. 2). Altogether, they 
help us to develop a deeper understanding of how cancers arise [4].  
 
Figure 2: Hallmarks of cancer [4] 
 
1.1.2 Subtypes 
There exist many different types of cancers and they all behave differently. They can 
grow at different rates and respond to different treatments. Also they display a huge 
genetic heterogeneity. According to their cells of origin, cancer types can be 
classified into different subtypes. Carcinomas arise from cells within epithelial 
structures, myelomas are derived from cells of the bone marrow, leukemias originate 
from cells of the hematopoietic lineage, lymphomas are coming from malignant cells 
belonging to the immune system, neuroectodermal tumors originate from the outer 
cell layer of the early embryo and sarcomas derive from mesenchymal cells [2]. 
Mesenchymal cells comprise bone, cartilage and connective tissues. This is why 
sarcomas can present almost anywhere in the body. We recognize more than 50 
subtypes of sarcomas. 
1.1.3 Childhood cancers 
Cancer is the second leading cause of death in children between the ages of 10 to 14 
years. Only a small minority of 1% of all cancer cases are childhood cancers. 
Cancers appearing in children are rarer and also very different from those developing 
in adults. Childhood cancers arise because of DNA changes, which happen very 
early in life and sometimes even before birth. Unlike adult cancers, there is no strong 
link to lifestyle or risk factors. With a few exceptions, children tend to tolerate and 
respond better to chemotherapy [5]. In general, only very few mutations are found in 
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childhood cancers [6, 7]. As a consequence of this, childhood cancers are dependent 
on fewer oncogenes. Also, childhood cancers differ from adult cancers in regard of 
their distribution and prognosis [8]. 
Carcinomas are the most frequent cancer type in adults, whereas children are more 
affected by leukemias, cancers of the central nervous system, lymphomas and soft 
tissue sarcomas (mainly Neuroblastoma and Rhabdomyosarcoma) [9]. Soft tissue 
sarcomas are far more common among children than in adults (Fig. 3).  
 
Figure 3: Frequency of cancner types in children and adults [7] 
 
 
1.2 Rhabdomyosarcoma 
The most common soft tissue sarcoma of childhood (50%) is Rhabdomyosarcoma 
(RMS) [10], a heterogeneous family associated with the skeletal muscle lineage [10-
13]. Typically, RMS presents at an age before 10 years and slightly affects more 
males than females. It approximately accounts for 3-4% of all pediatric cancers with 
an estimated frequency of 350 new cases per year for the United States [11-13]. 
1.2.1 Origin of RMS 
Almost all RMS cases occur sporadically. However, the disease is known to be linked 
to familial syndromes like Li-Fraumeni and neurofibromatosis, both of which are 
autosomal dominant disorders. This association most likely involves the inactivation 
of the p53 tumor suppressor gene by a germ line mutation (Li-Fraumeni) and 
hyperactivation of the RAS oncogene due to the loss of its negative regulator NF1 
also by mutation (neurofibromatiosis) [10, 13]. These rare conditions indicate that a 
key to understanding RMS is to investigate genes responsible for growth and 
development in early life. Because one third of all children with RMS carry congenital 
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anomalies, it is believed that prenatal events contribute to tumor development [14]. A 
complete family history is therefore important to have. Up until now, no carcinogens 
have been identified but marijuana or cocaine may be teratogenous during 
pregnancy and support the development of RMS [15]. 
Mutations in embryonic signaling pathways, which regulate muscle development and 
regeneration, can act as potential RMS oncogenes. They may be primary events or 
act as secondary cooperating mutations. Therefore they play a critical role in RMS 
tumorigenesis in addition to other genetic changes. Notch, WNT and Hedgehog 
signaling pathways play an important role in skeletal muscle differentiation by 
controlling the balance of proliferation versus differentiation [16]. 
Although the exact cell of origin for RMS is not known yet, skeletal muscle precursors 
are the main suspects. The current opinion is that RMS arises from mesenchymal 
stem cells (MSCs) [13, 17]. This is supported by the fact that they possess stem cell 
characteristics like self-renewal, high proliferation rates, senescence resistance and 
reversion of quiescence, which are shared with cancer cells [16]. Additionally, RMS 
tumors express multiple “stemness” and skeletal muscle markers. For this reason, 
RMS is believed to arise from stem-like cells of the myogenic lineage, which fail to 
undergo correct differentiation. As these cells are of embryonic origin, it supports the 
fact that it mainly occurs in children [12, 13, 16]. An alternative hypothesis states that 
differentiated muscle cells undergo mutations that stimulate dedifferentiation and 
self-renewal [16]. 
1.2.2 Subtypes of Rhabdomyosarcoma: eRMS and aRMS 
Histologically, rhabdomyosarcoma is classified as a small round blue cell tumor and 
can be divided into two subtypes (Fig. 4).  
 
Figure 4: Histological differences between embryonal RMS (left) and alveolar RMS (right) (hematoxylin-
eosin, 200x magnification) [18] 
Introduction  5 
 
Polo-like kinase 1 mediated phosphorylation regulates PAX3/FOXO1 in alveolar rhabdomyosarcoma 
The embryonal subtype (eRMS) shows similarities to embryonic developing muscles 
and accounts for about 70-80% of all RMS cases. The other subtype is called 
alveolar (aRMS) because it typically contains alveolar structures similar to those 
seen in the lungs and it constitutes another 20-30% of RMS cases [11-13, 16]. There 
is also a third and rather uncommon type of RMS, which is called anaplastic 
rhabdomyosarcoma and appears in adults. It grows quickly and requires intensive 
therapy [10, 13, 18]. 
These variants also display clinically distinct phenotypes. Whereas eRMS mainly 
occurs in patients younger than 10 years, aRMS affects children as well as 
adolescents and young adults. The head and neck region, genitourinary tract and 
retroperitoneum are sites to which eRMS is often localized. aRMS instead tends to 
occur in the extremities and trunk region [13, 18]. Generally, aRMS is more 
aggressive than eRMS and is associated with an unfavorable prognosis because of 
its tendency to form metastases, poor response to therapy and high frequency of 
relapse [10-12, 19].  
The differences between the subtypes are further reflected by the unique genetic 
features of eRMS and aRMS. A loss of heterozygosity at 11p15.5 in 80% and point 
mutations are often observed in eRMS [13]. This LOH seems to cause overactivation 
of the IGF2 gene, which could explain the growth of a tumor. In contrast, a 
characteristic feature of aRMS are chromosomal translocations occurring in 70-80% 
of all aRMS cases [16]. It is not exactly known what causes these genomic 
anomalities. Translocation positive aRMS displays an unfavourable prognosis (Fig. 
5). The remaining 20% of aRMS cases are fusion negative and have comparable 
genetic characteristics and clinical outcomes of eRMS tumors (Fig. 5) [12, 13]. 
 
Figure 5: Kaplan Meyer overall survival curves for eRMS (grey), fusion negative aRMS (blue) and fusion 
positive aRMS (yellow) [20] 
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1.2.3 The PAX3/FOXO1 fusion protein 
The most common translocation found in fusion positive aRMS is t(2;13)(q35;q14), 
which can be detected in 60% of cases. This event results in the formation of the 
oncogenic fusion protein PAX3/FOXO1. By this event, the DNA binding domain of 
PAX3 on chromosome 2 is fused to the transactivation domain of FOXO1 on 
chromosome 13 in an in-frame fashion (Fig. 6). In a similar way, the second most 
frequent fusion protein PAX7/FOXO1 is generated by a t(1;13)(p36;q14) 
translocation and is found in another 20% of aRMS [12]. These two translocations 
are specific to aRMS. In rare cases, a fusion between PAX3 and nuclear receptor 
coactivator genes NCOA1 and NCOA2 is found [21].  
 
Figure 6: Schematic representation of the PAX3/7-FOXO1 fusion protein [22] 
 
PAX3 and PAX7 belong to the family of paired box transcription factors. PAX3 plays 
a critical role in formation of various lineages during early embryonic development. 
Most importantly, it is necessary for the formation of skeletal muscle tissue [23]. In 
particular it is required for trunk muscle formation and delamination and migration of 
myogenic progenitor cells from the dermamyotome to the limb buds [24, 25]. 
Particularly, PAX3 controls cell survival, proliferation, and entry into myogenic 
program in these myogenic progenitor cells [26]. More than that, it regulates genes 
responsible for differentiation of neural crest cells, where it is also expressed during 
embryonic development, into more specialized cell types like nerve cells, craniofacial 
bones and melanocytes [24, 26-28]. PAX3 mutations are associated with 
Waardenburg-syndrome [25], which is characterized by deafness, pigmentation 
errors and facial dysplasia.  
FOXO1 is also a transcription factor belonging to the Forkhead box O subfamily. 
FOXO proteins are key regulators within a conserved pathway downstream of insulin 
and insulin-like growth factor receptors [29, 30]. The first forkhead gene was 
identified in Drosophila embryos and named after the changes of the head structure, 
which are seen upon mutation of this gene. They are involved in many cellular 
processes like proliferation, apoptosis, response to reactive oxygen species, 
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longevity, cell cycle regulation and metabolism [29, 31]. These transcription factors 
are regulated by posttranslational modifications and protein-protein interactions in 
response to conditional changes and cues [31, 32].  
The PAX3/FOXO1 fusion protein is a functionally hyperactive transcriptional regulator 
compared to PAX3 [33-35]. Gene expression and genome-wide binding studies 
showed that PAX3/FOXO1 transcriptional targets involve PAX3 target genes and 
others [36, 37], responsible for the inhibition of differentiation, promotion of cell 
survival and proliferation of myogenic cells [38]. Despite its oncogenic potential, 
PAX3/FOXO1 is generally not sufficient for complete transformation [12]. 
Additionally, it must cooperate with other genetic changes like INK4a/ARF and Trp53 
loss of function to finally lead to the formation of aRMS [39]. Important to mention is 
that the fusion status of aRMS tumors has prognostic value. Within the aRMS 
subgroup, the PAX3/FOXO1 fusion status is associated with the worst overall 
survival (Fig. 7) [12, 13, 19]. 
 
Figure 7: Kaplan Meyer plots of failure free survival for aRMS cases according to fusion status [40] 
 
1.2.4 Diagnostics and Therapy  
In parts of the body where the tumor can be recognized easily, RMS can often be 
found very early. As far as diagnostics are concerned, complete evaluation of a 
patient prior to treatment is necessary. This includes standard laboratory work as well 
as imaging techniques [10, 13]. However, the only way to confirm the diagnosis is to 
obtain a biopsy of the malignant mass for laboratory testing [10, 13]. All patients 
suffering from RMS require multimodal therapy. If possible, tumor resection is 
recommended followed by chemotherapy [10]. 
Depending on factors like subtype categorization, extent of distant disease, TNM 
classification and postsurgical residual disease, risk stratification is performed [10, 
13]. Radiation therapy is used to improve local control of postoperative residual 
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disease and outcome. But this application has limitations in young children due to 
late side effects by coradiation of surrounding structures [13]. 
All patients suffering from RMS receive chemotherapy. Usually, therapeutic regimens 
consist of a combination of vincristine, actinomycin-D, and cyclophosphamide [13]. 
This multimodal drug therapy in combination with risk stratification and cooperative 
clinical trials has led to immense advances in improving outcomes of patients with 
low and intermediate risk disease [41]. But only little progress in the field of advanced 
RMS has been made [13, 16]. Patients with high-risk disease still have a very poor 
five year overall survival rate of 20-30%. Especially for the aRMS subgroup of 
patients, almost no improvement was achieved [42]. This is mainly due to the lack of 
new agents and protocols, highlighting the importance to find new therapeutic 
approaches. So far, no targeted drug therapy is available for this tumor. 
 
1.3 Targeted therapy 
Targeted therapy has shown to effectively inhibit specific signal transduction 
pathways and therefore prevent tumor growth and even induce regression. Unlike 
classical chemotherapeutics, which affect all rapidly dividing cells, targeted therapy 
interferes with cancer specific molecules directly associated with carcinogenesis and 
tumor growth [43, 44]. Very often, cancer cells are dependent on the continuous 
activity of altered proteins or pathways (oncogene addiction) [45]. Therefore, targeted 
therapy is supposed to be more effective and have fewer side effects. The two main 
categories of substances in use are small molecules and monoclonal antibodies. 
Small molecules are able to penetrate the cells and act on intracellular targets, 
whereas monoclonal antibodies target antigens on the cell surface. Small molecules 
are designed to block the enzymatic activity of the target protein [44]. Tumors 
especially suitable for such a treatment have aberrations in upstream signaling 
cascade components, cell surface receptors or cytoplasmic kinases [46]. One of the 
first successfully applied small-molecule inhibitors was Gleevec, a tyrosine kinase 
inhibitor, targeting the BCR/ABL fusion protein in chronic myelogenous leukemia [47]. 
1.3.1 Targeting transcription factors 
A key role of oncogenic transformation can be attributed to transcription factors in a 
variety of cancers. In fact, transcription factors are the second most frequently 
mutated class of proteins found in human cancers [48]. In other cases, activity of 
transcription factors is altered by mutations in upstream signaling pathway 
components. Further, most oncogenic signaling pathways converge at sets of 
transcription factors as terminal effectors. Because many cancers are associated 
with aberrant gene expression patterns, transcription factors are promising targets for 
Introduction  9 
 
Polo-like kinase 1 mediated phosphorylation regulates PAX3/FOXO1 in alveolar rhabdomyosarcoma 
therapeutic strategies [44, 49-51]. However, it is difficult to directly target transcription 
factors with small molecules because of their predominant nuclear localization, which 
makes them less accessible, the lack of enzymatic activity and large surface areas of 
their functional domains, which are more difficult to target than deep binding pockets 
of kinases. Strategies for the indirect inhibition of transcription factor activity with 
small molecules include interfering with activation, subcellular translocation, 
interaction with other proteins, or DNA binding [44, 49-51].  
1.3.2 Targeting PAX3/FOXO1 in aRMS 
The major cancer specific aberrant target in aRMS is PAX3/FOXO1. Because the 
PAX3/FOXO1 chimeric transcription factor (no targetable enzymatic activity) lies at 
the end of intracellular signaling and is constantly located in the nucleus (resistant to 
Akt mediated regulation) [11], no direct inhibitors are available. Nevertheless, it has 
been shown that translocation positive RMS cells depend on the expression of 
PAX3/FOXO1. Downregulation of PAX3/FOXO1 by siRNA or antisense 
oligonucleotides reduced proliferation and motility, decreased invasion, induced 
differentiation and even led to induction of apoptosis [52-54]. These findings suggest 
that interfering with PAX3/FOXO1 expression is a possible therapeutic strategy. As it 
is, for reasons of technical complexity, rather difficult to transfer this method in vivo, 
clinical implementations are out of reach at the moment. Other mechanisms by which 
PAX3/FOXO1 could be indirectly inhibited are therefore interesting to investigate 
[46]. 
Strategies to indirectly target PAX3/FOXO1 involve the recognition of PAX3/FOXO1 
as a tumor antigen by immunotherapy [11]. Interfering with PAX3/FOXO1 interaction 
partners necessary for transcriptional activity might also be an interesting approach 
as well as restricting DNA binding at the epigenetic level by modulation of chromatin 
accessibility. Previous studies have shown that interfering with posttranslational 
modifications of PAX3/FOXO1 may be a useful strategy for the establishment of 
novel therapies. For example camptothecin, a topoisomerase I inhibitor, enhanced 
degradation of the fusion protein in aRMS cell lines probably by modulating its 
ubiquitination status [11]. Most importantly for this thesis, altering the phosphorylation 
status of either the C-terminal FOXO1 part, responsible for transactivation, or the N-
terminal PAX3 part, responsible for DNA binding, is a promising possibility [11].  
 
1.4 Regulation of transcription factors by phosphorylation 
One way by which the activity of transcription factors can be regulated is by 
phosphorylation. Phosphorylation can induce changes in properties like subcellular 
localization, protein stability, DNA-binding activity and protein-protein interactions 
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[55]. The following is meant to illustrate these changes based on a few examples. 
Afterwards, I want to shortly summarize what is known about phosphorylation in 
FOXO1 and PAX3. After all, this should clarify why interfering with phosphorylation of 
transcription factors could be a useful strategy for targeted cancer therapy. 
1.4.1 Examples 
Stability of the oncogenic transcription factor MYC is controlled by a series of events 
including phosphorylation. Phosphorylation at Ser 62, which is linked to Polo-like 
kinase 1 (PLK1), interferes with phosphodegron-mediated ubiquitinylation by FBW7 
ubiquitin ligase and subsequent proteasomal degradation of the protein. Therefore, 
MYC is stabilized. This event is triggered by activation of upstream PI3K signaling 
pathway [56, 57]. On the other hand, phosphorylation at Thr 58 promotes 
ubiquitylation and degradation of MYC [56]. 
The transcription factor CREB contains a transactivation domain, which is 
unstructured and inactive under normal conditions. Upon induction of adenyly 
cyclase (AC), in response to G protein coupled receptor activation, levels of the 
second messenger cAMP rise. This promotes the dissociation of protein kinase A 
(PKA) subunits. The caltalytic C subunits of PKA passively diffuse into the cell 
nucleus, where it phosphorylates the cAMP response element-binding protein 
(CREB) at Ser 133. Following this phosphorylation event, the transactivation domain 
undergoes a structural change allowing the interaction with CREB binding protein 
(CBP), which acts as a coaactivator [55, 58]. 
The interferon-regulated transcription factor IRF3, which plays an important role in 
innate immune systems response to viral infections, is modulated by multiple 
phosphorylation events within an autoinhibitory domain of the protein. If 
phosphorylated at these sites, the autoinhibitory domain unfolds and unmasks a 
region which is responsible for DNA binding, oligomerization and transactivation [55]. 
It activates the transcription of interferon alpha and beta as well as some other 
interferon induced genes. 
1.4.2 FOXO1 
Wild type FOXO1 activity is regulated by the canonical PI3K/AKT signaling pathway. 
This pathway is activated upon binding of growth factors to transmembrane receptor 
tyrosine kinases. Phosphorylation (Thr 24 / Ser 319, 256) of FOXO1 by AKT kinase 
(Fig. 8) promotes 14-3-3 protein binding and a subsequent sequestration in the 
cytoplasm [11, 30]. Therefore, FOXO1 is transcriptionally inactivated. Additionally, 
AKT-mediated phosphorylation at Ser 256 induces polyubiquitination and 
degradation of FOXO1 [59]. Of those three phosphorylation consensus sites found in 
wild type FOXO1, PAX3/FOXO1 retains two (Ser 319, 256). However, PAX3/FOXO1 
is resistant to this AKT mediated regulation and is consistently localized in the 
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nucleus. This is probably because nuclear localization in PAX3/FOXO1 is controlled 
by N-terminal PAX3 domains [11].  
The phosphorylation of FOXO1 at Ser 319 by AKT has been described to prime for 
subsequent phosphorylation of Ser 322 and Ser 325 by casein kinase 1 (CK1) (Fig. 
8) [60]. Together with Ser 329 phosphorylation, mediated by dual-specific YAK1-
related kinase 1 (DYRK1) (Fig. 8), this cluster was claimed to accelerate nuclear 
export by stimulating association with a protein complex containting the GTPase Ran 
[60]. 
Phosphorylation of FOXO1 by cyclin-dependent kinase 1 (Cdk1) at Ser 249 (Fig. 8) 
was described to block the interaction with 14-3-3 proteins, driving FOXO1 into the 
nucleus. Interestingly, Cdk2 can also phosphorylate FOXO1 at the same site but 
leads to an opposite output meaning cytoplasmatic localization and thereby inhibition 
[30, 31]. 
 
Figure 8: Overview of described phosphorylation sites in FOXO1 and the corresponding kinases with the 
forkhead domain depicted in grey [30] 
 
1.4.3 PAX3 
In contrast to FOXO1, phosphorylation of PAX3 is only poorly understood. Because 
wild type PAX3 is exclusively nuclear, it does not seem that subcellular localization is 
regulated by phosphorylation. Three phosphorylation sites (Ser 201, 205, 209) have 
been reported and the corresponding kinases have been identified. All three residues 
are retained in PAX3/FOXO1 [11]. 
It was shown that in proliferating primary myoblasts, casein kinase 2 (CK2) 
phosphorylates PAX3 as well as PAX3/FOXO1 at serine 205. Whereas this 
phosphorylation is lost on PAX3 upon induction of differentiation, it persists on 
PAX3/FOXO1 [24, 26, 28]. This first phosphorylation promotes a subsequent 
phosphorylation at Ser 201 by GSK3β. A third phosphorylation event is observed 
only in PAX3 after induction of differentiation. This phosphorylation at Ser209 could 
recently be linked to CK2 [28]. These findings suggest a distinct pattern of 
phosphorylation of PAX3 and PAX3/FOXO1 during early myogenic differentiation. 
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1.5 Previous Work 
1.5.1 Regulation of PAX3/FOXO1 by phosphorylation 
Through the analysis of gene expression data from therapeutic RMS biopsies, 
kinases with known tumorigenic capacity could be identified as possible targets. A 
series of kinase inhibitors against three of those kinases (EGFR, HGFR and FGFR) 
were then tested for their ability to reduce growth of different RMS cell lines. One 
compound with specific antigrowth and proapoptotic effect for the aRMS subgroup 
was PKC412, which induced apoptosis at submicromolar concentrations [46]. 
PKC412 inhibits several kinases like PKC, Akt, c-Kit, FLT3 and FGFR. PKC412 is 
currently evaluated as FLT3 inhibitor for the treatment of AML in a phase II clinical 
study.  
It could be shown that PKC412 has an inhibitory effect on the transcriptional activity 
of PAX3/FOXO1. Further, mass spectrometry data revealed that this effect is based 
on modulation of phosphorylation sites in the PAX3 part of the fusion protein. These 
sites lie within the linker region between the two DNA-binding domains (Fig. 9A). 
Interestingly, simultaneous mutation of all six serine residues into alanine (P3F 6xA) 
led to strongest reduction of transactivation potency (Fig. 9B). This was measured 
using a reporter cell line containing a plasmid, on which the luciferase gene was 
downstream of paired domain or homeodomain DNA binding sites [46]. 
 
Figure 9: PAX3/FOXO1 DNA binding activity is regulated by phosphorylation  
A) Schematic representation of the PAX3 domain structure with identified phosphorylation sites [46] B) Relative 
transactivation potencies of wt PAX3/FOXO1 and serine-alanine mutant PAX3/FOXO1 isoforms measured by 
luciferase reporter assay [46] 
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This suggests that a combination of phosphorylated sites is necessary for full 
transcriptional activity of PAX3/FOXO1. Because neither subcellular localization nor 
stability of PAX3/FOXO1 was affected, it was reasoned that DNA binding is 
decreased via the paired and the homeodomain.  
An independent study identified that Glycogen synthase kinase 3 (GSK3) inhibitors 
preferentially reduce cell growth of the aRMS subtype by screening 160 kinase 
inhibitors in RD (eRMS) and Rh30 (aRMS) cells. Induction of apoptosis after 
treatment was more effective in aRMS cells. Also reduced transcriptional activity of 
PAX3/FOXO1 upon GSK3 inhibition was demonstrated. It was further shown that 
GSK3 is able to phosphorylate PAX3/FOXO1 in vitro [61].  
Another study, which screened small molecule libraries, found that thapsigargin, an 
inhibitor of sarco/endoplasmic reticulum Ca2+ ATPase (SERCA), inhibited 
PAX3/FOXO1 transcriptional activity in reporter cells. It was revealed that this effect 
is mediated by AKT activation through thapsigargin. It was already published that 
AKT activation results in PAX3/FOXO1 phosphorylation in aRMS cells, which 
reduces its transcriptional activity [62]. They validated these findings and showed that 
this phoshphorylation event triggers PAX3/FOXO degradation by the proteasome 
pathway. An additional effect of thapsigargin treatment was reduced binding of 
PAX3/FOXO1 to regulatory elements of target genes. Further, thapsigargin blocked 
cell growth, survival and metastatic potential and was able to induce apoptosis in 
aRMS cells. Finally, thapsigargin treatment of human aRMS xenografts inhibited 
tumor growth in vivo [63]. 
Altogether, these findings suggest that small-molecule inhibition of kinases, which 
can influence the transcriptional activity of PAX3/FOXO1 by phosphorylation, is an 
alternative therapeutic approach in aRMS. 
1.5.2 Kinome Screening 
A functional RNAi screen of the human kinome was performed to identify upstream 
kinases with the ability to alter the transcriptional activity of PAX3/FOXO1. For this, 
Rh4 cells (aRMS cell line expressing PAX3/FOXO1) were transfected with a 
luciferase reporter plasmid containing the luciferase gene downstream of the 
AP2beta promoter (a known target of PAX3/FOXO1 [53]). A siRNA library containing 
3 unique siRNAs per gene against 719 kinases was used to produce knockdowns of 
the targets (Fig. 10). Almost one third of kinases that showed reduced luciferase 
activity after silencing (15 of 47 hits) had a previously described role in cancer. The 
remaining candidates could all be linked to either muscular and skeletal system 
disorders or genetic malignancies [64]. 
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Figure 10: siRNA kinome screening with PAX3/FOXO1 activity read-out [65] 
 
In a similar approach, the same reporter cell line (Fig. 10) was used to measure the 
effect of 125 different kinase inhibitors on PAX3/FOXO1 activity. From these two 
screening approaches, Polo-like kinase 1 (PLK1) was one of the top candidates for 
further investigations [65]. 
A different siRNA screening performed against 897 human phosphatases and 
kinases identified 16 phosphatases and 50 kinases with significant roles in growth 
control and survival in RMS cell lines. They found PLK1 to be one of the most 
important kinases supporting the survival of RMS. Silencing of PLK1 caused 
significant growth inhibition and apoptosis in RMS cells, whereas there was no effect 
observed in normal muscle cells. They additionally showed that other pediatric tumor 
cell lines were also highly sensitive to PLK1 inhibition [66].  
Taken together, these studies indicate that PLK1 is a promising candidate to target 
for the treatment of aRMS, since it is most probably involved in regulating the 
transcriptional activity of PAX3/FOXO1 and also because it is responsible for the 
survival of RMS cells. 
1.5.3 PLK1 as a novel therapeutic target 
PLKs are Ser/Thr kinases containing a conserved Polo-box domain, which mediates 
protein interactions. This module recognizes phosphopeptides with the consensus 
core consensus motif Ser-pThr/pSer-Pro/X. There are four different PLKs in 
mammals. PLK1 expression and protein levels are low through G1, 0 and S phase 
and rise in G2 with a peak during M phase [67, 68]. PLK1 has several mitotic roles 
involving entry into M phase, centriole and centrosome maturation, mitotic 
chromosome segregation with involvement in the spindle assembly checkpoint and 
cytokinesis. It is also involved in the DNA damage checkpoint [69, 70]. More than 
that, PLKs seem to timely coordinate cell division during embryonal development [67, 
68]. PLK1 is overexpressed in a variety of human tumors suggesting a role in 
carcinogenesis and has already been proposed as a therapeutic target [71-74]. 
Besides promoting proliferation, PLK1 overexpression contributes to carcinogenesis 
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by promoting chromosomal instability and aneuploidy [75]. Also, determination of 
PLK1 expression levels has prognostic value for different cancers. Elevated PLK1 
protein levels have been correlated with poor prognosis in non-small cell lung cancer, 
squamous cell carcinoma, esophageal carcinoma, melanoma, oropharyngeal 
carcinoma, breast cancer, colorectal cancer, and endometrial carcinoma [72]. In 
addition, it serves as a marker for high risk of metastasis. It was already shown that 
inhibition of PLK1 led to mitotic catastrophe that induced apoptosis in tumor cell lines. 
Several inhibitors targeting PLK1 are currently being developed and investigated in 
clinical trials [68, 76, 77]. 
1.5.4 In vitro and in vivo studies of PLK1 
Co-Immunoprecipitation experiments in aRMS cells revealed that PLK1 indeed 
interacts with PAX3/FOXO1 (Fig. 11A). Inhibition of PLK1 with siRNA or drug 
treatment reduced the expression of PAX3/FOXO1 target genes in aRMS cells (Fig. 
11B). Additionally, drug treatment reduced PAX3/FOXO1 protein levels in those cells 
(Fig. 11C). This effect could be rescued by the proteasomal inhibitor bortezomib. It 
was also shown that in xenograft mouse models, PLK1 inhibition by BI2536 caused 
remarkable tumor regression [65]. It is worth to mention that PLK1 is overexpressed 
in human aRMS tumors compared to normal muscle tissue samples [65, 66]. 
 
Figure 11: Preliminary data of in vitro studies of PLK1 [65]  
A) endogenous co-IP from Rh4 cell lysates with anti-FKHR(1) and anti-PAX3 antibody(2) showing interaction of 
PAX3/FOXO1 with PLK1 B) PAX3/FOXO1 target gene expression levels after siRNA knockdowns of PLK1 and 
PAX3/FOXO1 in Rh4 cells compared to scrambled siRNA treatment; CB1: cannabinoid receptor 1, FGFR4: 
fibroblast growt factor receptor 4, AP2beta; activating enhancer binding protein 2 beta, MYL1: myosin light chain 
1 C) PAX3/FOXO protein levels after treatment of Rh4 cells with different concentrations of PLK1 inhibitor after 48 
hours 
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These experiments consolidate PLK1 as a possible regulator of PAX3/FOXO1 
transcriptional activity. Further, these data show that PLK1 might have an influence 
on the stability of PAX3/FOXO1. Therefore, PLK1 is a potential therapeutic target in 
aRMS and required further investigation. 
 
1.6 Aim of thesis 
A first aim was to validate that PLK1 was regulating the transcriptional activity of 
PAX3/FOXO1.  
Another goal of my master thesis was to investigate whether PLK1 is indeed able to 
phosphorylate PAX3/FOXO1 as previous findings suggested. Further I wanted to 
identify the sites of phosphorylation within PAX3/FOXO1, because these sites are 
considered to play a role in the regulation of its transcriptional activity.  
The main part of my work was to test if any of these found phosphosites indeed have 
an influence on the transcriptional activity of PAX3/FOXO1. I also wanted to find out 
if any of the found phosphosites has an influence on the stability of PAX3/FOXO. 
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2 MATERIAL 
2.1 Media and Buffers 
2.1.1 Bacterial Media 
Table 1: Bacterial Media 
Media Components Amount 
Luria Bertani medium Bacto tryptone 10 g 
Yeast extract 5 g 
NaCl 10 g 
pH was adjusted to 7.5 with NaOH/HCl 
Water was added to a final volume of 1 l 
Sterilization was performed by autoclaving 
Luria Bertani medium with 
Agar for plates 
Bacto tryptone 10 g 
Yeast extract 5 g 
NaCl 10 g 
Bacto agar 15 g 
pH was adjusted to 7.5 with NaOH/HCl 
Water was added to a final volume of 1 l 
Sterilization was performed by autoclaving 
SOC medium Producer 
Invitrogen, Basel, Switzerland 
 
2.1.2 Cell culture Media 
Table 2: Cell culture Media 
Media Component Amount 
Complete Medium Dulbeccos modified Eagles Medium 
(DMEM) 
 
Fetal bovine serum (FBS) 10 % 
Penicilin 100 units/ml 
Streptomycin 100 units/ml 
L-glutamine 2 mM 
Mesenchymal Stem Cell 
Medium 
Producer 
Pelo Biotech Gmbh, Planegg, Germany 
 
2.1.3 General Buffers 
Table 3: General buffers 
Buffer Component Amount 
RIPA buffer Tris-Cl (pH=7.5) 50 mM 
NaCl 150 mM 
NP 40 1% 
Na-Deoxycholate 0.5% 
SDS 0.1% 
EGTA 1 mM 
NaF 50 mM 
-Glycerolphosphat 10 mM 
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Natrium Pyrophosphat 5 mM 
Na3VO4 1 mM 
Complete protease inhibitor 1x 
Lysis buffer Tris-Cl (pH=7.5) 50 mM 
NaCl 125 mM 
NP 40 1% 
MgCl2 1.5 mM 
NaF 25 mM 
-Glycerolphosphat 10 mM 
Natrium Pyrophosphat 5 mM 
Na3VO4 2 mM 
Complete protease inhibitor 1x 
Wash buffer Tris-Cl (pH=7.5) 50 mM 
NaCl 150 mM 
CIP 1x reaction buffer Tris-Cl (pH= 7.5) 50 mM 
MgCl2 1 mM 
ZnCl2 0.1 mM 
PLK1 5x reaction buffer HEPES (pH=7.5) 250 mM 
MgCl2 50 mM 
DTT 12.5 mM 
Triton X-100 0.05% 
ATP 200 M 
CH buffer Tris-Cl (pH=8.0) 20 mM 
NaCl 500 mM 
Triton X-100 0.1% 
EDTA 1 mM 
Glycerol 10% 
10x TBS-Tween Tris-Cl (pH=7.5) 60.5 g 
NaCl 87.6 g 
H2O 800 ml 
pH was adjusted to 7.5 with HCl 
Water was added to a final volume of 1 l 
Tween 20 10 ml 
Mixing solution H2O 50 ml 
1M HEPES 125 l 
2xHeBS NaCl 0.28 M 
HEPES 0.05 M 
Na2HPO4 1.5 mM 
H2O 800 ml 
pH was adjusted to 7.0 with NaOH, H2O was added to a 
final volume of 1 l 
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2.2 Cell lines 
Table 4: Cell lines 
Cell line Source 
Rh3 Susan Ragsdale, St.Jude Children`s Research Hospital, 
Memphis TN, USA  
Rh4 Peter Houghton, The Research Institute at Nationwide 
Children's Hospital, Columbus, OH, USA  
RMS13 Roland Kappler, Ludwig-Maximilians-Universität München, 
Germany 
RMS Janet Shipley, Institute of Cancer Research, London, GB 
RD American Type Culture Collection (ATCC)  
mMSC Life Technologies, Oslo, Sweden 
HS5 American Type Culture Collection (ATCC) 
Primary hMSC Pelo Biotech Gmbh, Planegg, Germany 
C2C12 American Type Culture Collection (ATCC) 
Phoenix ampho American Type Culture Collection (ATCC) 
293 GPG Richard C. Mulligan, Children's Hospital, Boston, MA, USA 
 
2.3 Kits 
Table 5: Kits 
Product Producer 
QIAGEN Plasmid Mini Kit Qiagen, Basel, Switzerland 
In-Fusion HD cloning Kit Clonetech, Saint-Germain-en-Laye, 
France 
jetPRIME Polyplus transfections, Basel, 
Switzerland 
Pierce BCA protein assay Kit Thermo Scientific, Reinach, Switzerland 
RNeasy Mini Kit Qiagen, Basel, Switzerland 
QIAquick Gel Extraction Kit Qiagen, Basel, Switzerland 
High capacity cDNA reverse transcription 
Kit  
Applied Biosystem, Zug, Switzerland 
 
2.4 Antibodies 
Table 6: primary antibodies 
Antibody Host organism Producer 
Anti-FOXO1 H-128 Rabbit Santa Cruz Biotech, USA 
Anti-Actin Rabbit Cell signaling, Danvers, USA 
Anti-GAPDH Rabbit Cell signaling, Danvers, USA 
Anti-Cyclin B1 Rabbit Cell signaling, Danvers, USA 
Anti-Flag Mouse  Sigma-Aldrich, Buchs, Switzerland 
Anti-FOXO1 (p322) Rabbit Abcam, Cambridge, UK 
 
Table 7: secondary antibody 
Antibody Host organism Producer 
Anti-rabbit HRP-linked Anti-rabbit Cell signaling, Danvers, USA 
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2.5 Solutions 
Table 8: Solutions 
Product Producer 
20xNuPAGE SDS Running buffer  Invitrogen, Basel, Switzerland  
20xNuPAGE Transfer buffer  Invitrogen, Basel, Switzerland 
25xTAE buffer Life Technologies, Oslo, Sweden 
Chemiluminiscence detection reagents 
ECL  
GEHealthcare, Amersham, Switzerland  
Dimethylsulfon (DMSO)  Sigma-Aldrich, Buchs, Switzerland  
DMEM  Sigma-Aldrich, Buchs, Switzerland 
Dynabeads Life Technologies, Oslo, Sweden 
FBS  Invitrogen, Basel, Switzerland 
GelRed Biotium, Hayward, USA 
Non-fat dry milk  Migros, Zurich, Switzerland  
10xPhosphate buffered saline (PBS)  Sigma-Aldrich, Buchs, Switzerland 
Super signal West Femto Maximum 
Sensitivity Substrate  
Thermo scientific, Reinach, Switzerland  
TaqMan Gene Expression Master MIx  Applied Biosystem, Zug, Switzerland  
Trypsin/Ethylenediaminetetraacetic 
(EDTA)  
Bioconcept, Allschwill, Switzerland  
 
2.6 Chemicals and enzymes 
Table 9: chemicals and enzymes 
Product Producer 
4% Formalin Carl Roth, Arlesheim, Switzerland  
Agarose Eurogentec, Seraing, Belgium 
Ampicillin Sigma-Aldrich, Buchs, Switzerland 
Bacto-Agar BD, Allschwill, Switzerland  
Bacto-Tryptone BD, Allschwill, Switzerland  
CaCl2 Sigma-Aldrich, Buchs, Switzerland 
Chloramphenicol Fluka, Buchs, Switzerland 
CIP (Calf intestinal phosphatase) Promega, Fitchburg, Madison, USA 
Complete protease inhibitor Roche, Reinach, Switzerland  
Cycloheximide Fluka, Buchs, Switzerland 
DpnI Thermo scientific, Reinach, Switzerland 
DTT Sigma-Aldrich, Buchs, Switzerland 
EGTA Sigma-Aldrich, Buchs, Switzerland 
Ethanol  Kantonsapotheke Zurich, Switzerland  
Glycerol Sigma-Aldrich, Buchs, Switzerland 
IPTG Eurogentec, Seraing, Belgium 
L-Glutamine Bioconcept, Allschwill, Switzerland 
Methanol Hänseler AG, Herisau, Switerland 
MgCl2 Sigma-Aldrich, Buchs, Switzerland 
Na3VO4 Sigma-Aldrich, Buchs, Switzerland 
NaCl Sigma-Aldrich, Buchs, Switzerland 
Na-Deoxycholate Sigma-Aldrich, Buchs, Switzerland 
NaF Sigma-Aldrich, Buchs, Switzerland 
Natrium Pyrophosphat Sigma-Aldrich, Buchs, Switzerland 
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NP 40 Fluka, Buchs, Switzerland  
Penicillin Invitrogen, Basel, Switzerland 
PLK1 recombinant kinase Invitorgen, Basel, Switerland 
PMSF Sigma-Aldrich, Buchs, Switzerland 
Polybrene Fluka, Buchs, Switzerland 
Ponceau Sigma-Aldrich, Buchs, Switzerland 
RNase-Free DNase Set Qiagen, Basel, Switzerland 
SDS Sigma-Aldrich, Buchs, Switzerland 
Streptomycin Invitrogen, Basel, Switzerland 
Tetracycline Fluka, Buchs, Switzerland 
Tris-Cl (pH=7.5) Sigma-Aldrich, Buchs, Switzerland 
Triton X-100 Sigma-Aldrich, Buchs, Switzerland 
Tween 20 Sigma-Aldrich, Buchs, Switzerland 
Yeast extract BD, Allschwill, Switzerland  
XhoI Thermo scientific, Reinach, Switzerland 
-Glycerolphosphat Sigma-Aldrich, Buchs, Switzerland 
 
2.7 Plasmids 
Table 10: plasmids 
Plasmid name Gift from Backbone Producer,  
product number 
pMSCV-IRES-GFP Dr. Elisa Zimmermann Addgene, no. 33336 
pMSCV-PAX3/FOXO1-IRES-GFP Dr. Elisa Zimmermann Addgene, no. 33336 
pcDNA3-PAX3/FOXO1  
(6xA, S201A, S205A, G48S, 
N269A) 
Dr. Marco Wachtel Invitrogen, V790-20 
pCMV-NFlag-PAX3/FOXO1 Verena Thalhammer Stratagene, 240229 
pTXB1 Dr. Laura Lopez New England Biolabs, 
N6707S 
 
2.8 Software 
Table 11: Software 
Product Producer 
FlowJo  Tree Star Inc., Ashland, USA  
SDS 2.2 Rasband, W.S., National Institutes of Health, 
Bethesda, Maryland, USA  
ImageJ Applied Biosystem, Zug, Switzerland  
Prism 6 trial www.graphpad.com 
Clone manager Scientific & Educational Software, Cary, USA 
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3 METHODS 
3.1 Bacteria and Cloning 
3.1.1 Transformation of competent bacteria 
Transformation of competent Escherichia Coli (DH5) is the method to amplify 
plasmid DNA through cellular replication. For each transformation, an aliquot of 50 l 
competent bacteria was thawed on ice. Afterwards, 1l of plasmid DNA recovered 
with Miniprep Kit or 2 l of In-Fusion HD cloning Kit Reactions were added. The 
mixture then was incubated on ice for 12 minutes. Heat shock was performed in a 
water bath at 42°C for 2 minutes, followed by a 2 minutes incubation on ice. 400 l of 
prewarmed SOC medium were added and the mixture was incubated for 1h at 37°C 
shaking at 200 rpm. Finally, 100 l of the transformation mixture were plated on agar 
plates containing the appropriate antibiotic (e.g. 100 g/ml Ampicillin). The plates 
were incubated at 37°C overnight. 
3.1.2 Plasmid Miniprep 
Single colonies were picked and used to inoculate 5ml of LB medium containing the 
appropriate antibiotic (e.g. 100 g/ml Ampicillin). The inoculates were incubated 
overnight at 37°C. The next day, bacteria were pelleted by centrifugation at 4000 rpm 
for 10 minutes. The supernatant was discarded and the QIAprep Spin Miniprep Kit 
protocol was followed. DNA was eluted in 50 l H2O. Concentrations of plasmid DNA 
were determined by measuring OD260nm using the NanoDrop ND-1000 
Spectrophotometer.  
3.1.3 Site directed mutagenesis of PAX3/FOXO1 
Mutagenesis was performed using QuikChange (Stratagene) recommendations. As a 
first step, mutagenic primers were designed using clone manager software. By using 
the PAX3/FOXO1 coding sequence, the codon coding for each amino acid to be 
mutated was determined. By changing nucleotides, codons coding for alanine (or 
aspartic acid) were generated. Complementary primers of 40-42 bp were designed 
with the desired mutations in the middle of the primers. The primers were generated 
by Microsynth. A list of all primers used for mutagenesis is shown below.  
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Table 12: primers used for site directed mutagenesis 
Primer name  Primer sequence 
P3F_S30A_F 5’-GTT CCC GCT GGA AGT GGC CAG TCC CCT CGG CCA 
GGG CCG CG-3’ 
P3F_S30A_R 5’-CGC GGC CCT GGC CGA GGG CAG TGG ACA CTT CCA 
GCG GGA AC-3’ 
P3F_T31A_F 5’-GTT CCC GCT GGA AGT GTC CGC TCC CCT CGG CCA GGG 
CCG CG-3’ 
P3F_T31A_R 5’-CGC GGC CCT GGC CGA GGG GAG CGG ACA CTT CCA 
GCG GGA AC-3’ 
P3F_T31D_F 5’-GTT CCC GCT GGA AGT GTC CGA TCC CCT CGG CCA GGG 
CCG CG-3’ 
P3F_T31D_R 5’-CGC GGC CCT GGC CGA GGG GAT CGG ACA CTT CCA 
GCG GGA AC-3’ 
P3F_S389/393A_F 5’-AAT GGC CTC GCA CCT CAG AAT GCA ATT CGT CAT AAT 
CTG TCC-3’ 
P3F_S389/393A_R 5’-AGA TTA TGA CGA ATT GCA TTC TGA GGT GCG AGG CCA 
TTG CC-3’ 
P3F_S399A_F 5’-ATT CAA TTC GTC ATA ATC TGG CCC TAC ACA GCA AGT 
TCA TTC G-3’ 
P3F_S399A_R 5’-CGA ATG AAC TTG CTG TGT AGG GCC AGA TTA TGA CGA 
ATT GAA T-3’ 
P3F_S399/402A_F 5’-TCA TAA TCT GGC CCT ACA CGC CAA GTT CAT TCG TGT 
GC-3’ 
P3F_S399/402A_R 5’-CGA ATG AAC TTG GCG TGT AGG GCC AGA TTA TGA CGA 
ATT G-3’ 
P3F_S503A_F 5’-ACT AGC TCA AAT GCT ACT ATT AGT GGG AGA CTC TCA 
CC-3’ 
P3F_S503A_R 5’-GGT GAG AGT CTC CCA CTA ATA GTA GCA GCA TTT GAG 
CTA GT-3’ 
P3F_510A_F 5’-TAC TAT TAG TGG GAG ACT CGC ACC CAT TAT GAC CGA 
ACA GG-3’ 
P3F_510A_R 5’-CCT GTT CGG TCA TAA TGG GTG CGA GTC TCC CAC TAA 
TAG TA-3’ 
 
In a second step, a PCR reaction mix was prepared as shown below. 
Table 13: PCR reaction mix for site directed mutagenesis 
Component Amount 
pMSCV-P3F-IRES-GFP plasmid DNA 0.5 l ( 25 ng) 
Forward primer (10 M) 1.25 l 
Reverse primer (10 M) 1.25 l 
Accu Prime Pfx DNA Polymerase 0.3 l 
10x Accu Prime reaction mix 2.5 l 
H2O  19.2 l 
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The cycling conditions for the PCR were as follows. For some reactions, cycle 
numbers and annealing temperature had to be modified. 
94°C  2 min 
94°C  30 sec 
55°C  1 min 
68°C  12 min 
68°C  7 min 
4°C   
1.2 l of DpnI enzyme was directly added to the reaction mix and incubated at 37°C 
for 3 hours to digest parental plasmid DNA. It was verified on an agarose gel that the 
PCR reaction was successful. Competent bacteria were transformed and the next 
day, colonies were picked for Minipreps. Sequencing was done by Microsynth.  
3.1.4 Subcloning 
Subcloning of PAX3/FOXO1 DNA sequences was performed following the In-Fusion 
HD cloning Kit protocol. As a first step, the target vector (pMSCV-IRES-GFP or 
pTXB1) had to be linearized by restriction enzyme digestion. In our case we always 
used XhoI. The digestion mix was incubated overnight at 37°C.  
Table 14: Digestion reaction mix for subcloning 
Coponent Amount 
Target vector plasmid DNA 2 g (x l) 
XhoI 2 l 
NEB3 buffer (10x) 2 l 
H2O To total volume of 20 l 
 
Secondly, a PCR of PAX3/FOXO1 was made using primers with 15 bp 5’ extensions 
complementary to the ends of the linearized vector. The primers were designed using 
clone manager software. A summary of all primers used for subcloning is shown 
below.  
Table 15: Primers used for subcloning  
Primer name  Primer sequence 
pMSCV_P3Fumkl_F 5’-GAA TTC AGA TCT CGA ATG ACC ACG CTG GCC GGC-3’ 
pMSCV_P3Fumkl_R 5’-ATT GAT CCC GCT CGA TCA GCC TGA CAC CCA GCT-3’ 
pTXB1_P3Fumkl_F 5’-CCG CGA ATT CCT CGA ATG ACC ACG CTG GCC GGC-3’ 
pTXB1_P3Fumkl_R 5’-AGG AAG AGC CCT CGA TAA GCC TGA CAC CCA GCT-3’ 
 
The PCR was conducted according to the suggested conditions mentioned in the 
Phusion High-Fidelity DNA Polymerase Product Information sheet.  
It was verified on an agarose gel that the vector was linearized and the target DNA 
was amplified. The bands were excised from the gel and DNA was extracted using 
the QIAquick Gel Extraction Kit. DNA concentrations were determined using the 
NanoDrop ND-1000 Spectrophotometer. The In-Fusion reaction was set up and 
16 cycles 
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conducted as described in the In-Fusion HD Cloning Kit protocol. Competent bacteria 
were transformed with 2 l of the reaction mix. The next day, colonies were picked 
for Minipreps. Sequencing was performed by Microsynth. 
 
3.2 Cell culture 
3.2.1 Thawing, Splitting and Freezing of cell lines 
aRMS cell lines, mMSCs and Phoenix ampho cells were cultured in complete 
medium. C2C12 cells were cultured in complete medium with 20% FBS to prevent 
differentiation. 293 GPG cells were cultured in complete medium with 1 g/ml 
tetracycline, except for periods of virus production. Primary hMSCs were cultured in 
mesenchymal stem cell medium. All cells were incubated at 37°C and 5% CO2. 
1ml aliquots of frozen cell lines were thawed in a 37°C water bath and transferred in 
a falcon tube with 9ml culture medium. Then the cells were centrifuged for 5 minutes 
at 1200 rpm. The supernatant was removed and the pellet was resuspended in the 
correct volume of complete medium required for the size of corresponding culture 
dishes. 
Cell lines were split when they reached approximately 80% confluency. The medium 
was removed from the cells followed by a washing step with 1xPBS. Cells were 
incubated for 3-5 minutes with Trypsin/EDTA at 37°C. After resuspending the cells in 
complete medium, the desired fraction was transferred in a new cell culture dish and 
complete medium was added to the final volume required. 
For long-term storage, cells were frozen in freezing medium consisting of complete 
medium with 10% DMSO. Cells were trypsinized and after addition of medium 
centrifuged for 1200 rpm 5 minutes. The pellet was resuspended in freezing medium 
and aliquots of 1 ml were transferred into cryotubes. For short-term storage, 
cryotubes were put in -80°C. For longer storage periods, cryotubes were transferred 
into the liquid nitrogen tank. 
3.2.2 siRNA Knockdowns 
All transient siRNA mediated knockdown experiments in aRMS cell lines were 
performed following the instructions of the INTERFERin Easy protocol. For this, cells 
were transfected with PLK1 specific siRNA (s449) or scrambled siRNA as a control 
using INTERFERin. All experiments were performed in 6-well format using 200’000 
cells. Cells were collected 48 hours or 72 hours after transfection for further analysis. 
Table 16: silencer select siRNAs for knockdown experiments 
Gene name Silencer Select siRNA ID 
Scrambled  2 (negative control) 4390846 
PLK1 s449 
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3.2.3 Transient transfections 
In my experiments I used two different protocols for transient transfections of cells. 
For transfections with Jet-Prime, cells were seeded the day before transfection 
(Table 17). 1.5 ml Eppendorf tubes were prepared with the appropriate JetPrime 
buffer volume and according amounts of plasmid DNA was added. The tubes were 
vortexed and briefly centrifuged. Then JetPrime reagent was added and the tubes 
were again vortexed and centrifuged (Table 17). The reaction mix was then 
incubated at room temperature for 10 minutes to allow formation of DNA precipitate. 
Medium on the cells was changed and the reaction mix was directly added dropwise 
to the fresh medium. The next day, medium was changed again. 
Table 17: conditions for Jet-Prime transfections 
Culture 
Vessel 
Number of 
cells seeded 
Volume of 
JetPrime 
buffer (l) 
Amount of 
DNA (g) 
Volume of 
JetPrime 
reagent (l) 
Volume of 
growth 
medium (ml) 
6-well 200’000 200 1  2 2 
10 cm 2.5 Mio 500 10 20 10 
 
For transfections with calcium phosphate, 6.5 Mio HEK293T cells were plated in a 15 
cm plate the day before transfection. 24 hours later, medium was changed. 50 g of 
plasmid DNA were added to 0.5 ml mixing solution. To this mixture, 0.5 ml of 0.5 M 
CaCl2 was added. Then, 1 ml of 2xHeBS was added dropwise while vortexing. After 
incubation for 15 minutes at room temperature, the solution was added dropwise to 
the plate. The next day, medium was changed. 
3.2.4 Retroviral transductions 
Packaging cell lines allow production of infectious viral particles. In my experiments I 
used two different packaging cell lines for the production of retrovirus. 
The 293 GPG packaging cell line, based on HEK293T cells, is considered to produce 
high titers of amphotropic retrovirus. 293 GPG cells are stable transfected with 
packaging plasmids, containing the Gag and Pol genes from MoMLV (Moloney 
Murine Leukemia Virus) and the VSV-G gene from vesicular stomatitis virus. Gag 
encodes for the viral matrix-, capsid- and nucleocapsid proteins. Pol encodes for the 
viral enzymes protease, reverse transcriptase and integrase. The VSV-G gene 
encodes the envelope glycoprotein, which interacts with host cell receptors and is 
responsible for the broad range of tropism of the virus. Because the VSV-G coat 
protein is toxic to 293 GPG cells, its expression is repressed during cell growth via a 
TET repressor. This is why cells were kept in DMEM containing 1 g/ml tetracycline, 
except for periods of virus production.  
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The Phoenix ampho packaging cell line has also been engineered based on 
HEK293T cells. It contains the same Gag and Pol genes from MoMLV as 293 GPG 
cells. In contrast to the 293 GPG cells, this cell line contains an amphotropic 
envelope gene from MoMLV instead of the VSV-G glycoprotein. This cell line 
produces viral particles able to infect most dividing cell types. The Phoenix ampho 
cell line can be cultured in complete medium without any additives.  
On day 0, packaging cells were plated. Seeding was performed with 2.5 Mio cells per 
10 cm dish in DMEM. 293 GPG cells were plated in DMEM without Tetracyclin. 24h 
later, the medium was changed and the packaging cells were transfected with 
retroviral plasmid containing PAX3/FOXO1 (wild type or mutants) (Fig. 12), using the 
Jet-Prime Protocol.  
 
Figure 12: plasmid constructs used for retrovirus production 
Another 24h later, the medium was changed again. Then cells were kept in culture to 
allow the production of viral particles. 72h post transfection, the virus supernatant 
was collected in a 50 ml Falcon tube and centrifuged for 4min at 1200 rpm to get rid 
of cellular components. After that, virus supernatant was filtered using a 0.45 nm 
cellulose acetate membrane filter tip. If virus supernatant was not directly used to 
infect cells, aliquots of 2-5 ml were frozen and stored at -80°C for later use.  
24h before infection, 150’000 RD cells were plated per well of a 6-well plate in 
DMEM. Same amounts of cells were plated for mMSC, HS5, HEK293T and Rh4 cell 
lines. Primary hMSCs were plated in a density of 80’000 cells per well. The day of 
infection, medium was removed from target cells and replaced with virus 
supernatant. Polybrene was added to a final concentration of 10 g/ml. Plates were 
securely closed with parafilm and centrifuged for 1h at 32°C and 800 g. Alternatively, 
infection was conducted by incubating the cells with virus supernatant overnight 
either once or twice. Then, virus supernatant was removed from target cells. 
Washing with 1 ml 1xPBS per well was performed twice before adding 2ml of fresh 
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medium to each well. Analysis of samples was performed after 48 – 192h post 
infection. The procedure of retrovirus production and target cell infection is 
summarized in Fig. 13. 
 
 
Figure 13: Representation of workflow for the retroviral PAX3/FOXO1 activity read out system  
Packaging cell lines are represented in blue and target cells are represented in green 
 
3.2.5 Cycloheximide treatments 
Cycloheximide (CHX) is a compound interfering with the translocation step in protein 
synthesis and therefore inhibits translation. CHX treatment is a probate tool to 
investigate the stability of proteins.  
200’000 cells were seeded the day before transfection in a well of a 6-well plate. 24 
hours later, the cells were transfected with 1 g plasmid DNA using the JetPrime 
protocol. The cells were incubated overnight (12-17h). Stock solutions of CHX 
(diluted in DMSO) were diluted in DMEM to reach the desired concentration of 35 
M. As a control, a solution with the same volume of DMSO was prepared. After the 
medium was removed from the cells, it was replaced with drug solution or DMSO 
solution. Protein was isolated and analyzed by Western blot at the indicated time 
points after treatment. 
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3.3 Quantification of gene expression level 
3.3.1 RNA isolation 
For RNA extraction, the RNeasy Mini Kit protocol was applied. As an optional step, 
DNase incubation for 15 minutes was performed to prevent genomic DNA 
contamination. RNA was eluted in 30 l RNase-free H2O and concentrations were 
determined by measuring OD260nm with the NanoDrop ND-1000 
Spectrophotometer. 
3.3.2 cDNA synthesis 
For reverse transcription of RNA into complementary DNA, a high capacity reverse 
transcription kit was used. After RNA concentrations were determined, 1 g RNA of 
all samples was diluted in water to a volume of 26.4 l in a PCR tube. To this dilution, 
13.6 l of RT master mix (Table 18) was added. 
Table 18: RT master mix for cDNA synthesis 
Component Amount 
10xRT Buffer 4 l 
dNTPs 1.6 l 
10x random Primers 4 l 
Reverse Transcriptase 2 l 
RNase Inhibitor 2 l 
 
The resulting 40 l reaction mix was put in a T3000 Thermocycler and reverse 
transcription was performed as follows: 
10 min 25°C (annealing), 2h 37°C (reverse transcription), 5 sec 85°C (denaturation) 
3.3.3 qRT-PCR 
This method is designed to allow quantification of the increase of amplified templates 
per cycle of a PCR reaction. For this, template specific oligonucleotide probes 
containing a 5’-reporter fluorophore and a 3’-quencher are used. During synthesis of 
new amplicons, the 3’-exonuclease activity of the Taq-Polymerase degrades the 
probe. Because energy transfer from the fluorophore to the quencher can no longer 
take place, fluorescence can be detected. Measurements of fluorescence take place 
at the end of every elongation step during the entire PCR reaction. Proportional to 
the amplified template, also the fluorescence increases with each cycle. The cycle 
number at which the fluorescence exceeds a certain threshold, called CT value, is 
recorded.  
For each qRT-PCR reaction, a mix containing 5 l TaqMan Gene expression Master 
Mix and 0.5 l gene specific TaqMan assay (Table 19) was prepared. 
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This mix was transferred to a well of a 384-well plate and 4.5 l cDNA dilution (0.7 l 
cDNA and 3.8 l H2O) was added. For each sample, reactions were performed in 
triplicates. The plates were closed with a clear adhesive cover, briefly centrifuged 
and put in the 7900HT Fast Real-Time PCR machine.  
Analysis of the data was conducted with SDS2.2 software using the CT method. 
Like this, the relative expression levels of the measured genes could be determined. 
In all experiments the housekeeping gene Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) was used for normalization.  
 
CT method: 
CT values for all samples were determined by calculating the difference between 
CT values of the target gene and the CT value of GAPDH. 
 CT (sample)= CT (target gene) – CT (GAPDH) 
CT values were determined by calculating the difference between CT values of 
the samples and the reference sample. 
 CT (sample)= CT (sample) - CT (reference sample) 
The normalized level of gene expression for each sample was calculated using the 
formula: 
 Gene expression level= 2-CT 
 
Table 19: TaqMan gene expression assays for qRT-PCR
 
Gene name TaqMan assay number Producer 
PAX3/FOXO1  Hs03024825_ft Applied Biosystem, Zug, Switzerland 
PAX3 Hs00240950_m1 Applied Biosystem, Zug, Switzerland 
FGFR4 Hs01106908_m1  Applied Biosystem, Zug, Switzerland 
AP2beta Hs00231468_m1  Applied Biosystem, Zug, Switzerland 
CDH3 Hs00354998_m1 Applied Biosystem, Zug, Switzerland 
MYL1 Hs00984899_m1  Applied Biosystem, Zug, Switzerland 
PIPOX Hs04188866_m1 Applied Biosystem, Zug, Switzerland 
MYCN Hs02330075_m1 Applied Biosystem, Zug, Switzerland 
MYOD Hs02330075_g1 Applied Biosystem, Zug, Switzerland 
DUSP4 Hs01027785_m1 Applied Biosystem, Zug, Switzerland 
TNNC2 Hs00268519_m1 Applied Biosystem, Zug, Switzerland 
MET Hs01565584_m1 Applied Biosystem, Zug, Switzerland 
PRKAR2B Hs00176966_m1 Applied Biosystem, Zug, Switzerland 
POU4F1 Hs00366711_m1 Applied Biosystem, Zug, Switzerland 
CB1 Hs01038522_s1 Applied Biosystem, Zug, Switzerland 
GAPDH Hs02758991_g1  Applied Biosystem, Zug, Switzerland 
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3.4 Determination of Protein levels 
3.4.1 Protein isolation 
After washing with 1ml PBS, cells were lysed with 35-100 l of cold RIPA buffer per 
6-well depending on the confluency of the cells. Then the plates were scraped with a 
cell scraper and the lysate was collected in a 1.5 ml Eppendorf tube. Incubation was 
performed for 10 minutes on ice. Afterwards cell lysates were treated with 4 cycles of 
40 seconds of sonification in a water bath followed by 1 minute incubation on ice 
after each cycle. Alternatively, cell lysates were pressed through a 25G needle 
several times. Finally, cell lysates were centrifuged at 4°C for 10 minutes at 10’000 
rpm. The supernatant was collected and protein concentration was determined using 
the Pierce BCA Protein Assay Kit. 
3.4.2 Western Blot 
Protein lysates were mixed with 4xRotiLoad (or 4xLDS with 1 M DTT, 4:1) in 
appropriate amounts. This mixture was incubated at 70°C for 3-5 minutes. After 
cooling of the samples, equal amounts of protein were loaded on a NuPage 4-12% 
Bis-Tris Gel. Gel electrophoresis was performed in 1xNuPAGE SDS running buffer 
first at 80 V and later at 150 V until separation was completed. For blotting onto 
nitrocellulose membranes, the blotting sandwich was put in a blotting module and run 
in 1xNuPAGE transfer buffer at 33 V for 2 hours. To prevent heating, cold water with 
ice was filled around the chamber. Then the membrane was stained in Ponceau 
solution to check for blotting efficiency and shortly destained in H2O. To prevent non-
specific binding of antibodies, the membrane was blocked in 5% non-fat dry milk in 
1xTBST solution (1xTBS and 0.1% Tween) for 30 minutes on a shaker. The 
membrane was incubated with primary antibody against the protein of interest, which 
was diluted in 1xTBST containing either 5% BSA (for phospho antibodies) or 5% 
non-fat dry milk. Incubation of the membrane in primary antibody was conducted 
overnight at 4°C. The next day, the membrane was washed 3 times for 10 minutes in 
1xTBST. This was followed by incubation for 1 hour at room temperature in 
secondary antibody directed against the species-specific part of the primary antibody. 
The secondary antibody was diluted in 1xTBST 5% non-fat dry milk. Afterwards, the 
membrane was again washed 3 times for 10 minutes in 1x TBST. The membranes 
were incubated for 1 minute in 6 ml ECL chemoluminescence detection reagents 
mixture (A and B, 1:1). Chemoluminescence signal was detected with the LAS-3000 
imaging system. 
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3.5 Flow cytometry 
3.5.1 Estimating infection efficiency 
After washing with 1xPBS, cells were detached from culture plates using trypsin. 
After addition of complete medium, the cells were transferred to a 15 ml falcon tube 
and centrifuged for 5 minutes at 1’200 rpm. The supernatant was aspirated. 200 l of 
4% Formalin solution were added and incubation was performed on ice for 10 
minutes. 1 ml of 1xPBS was added to the cells followed by another round of 
centrifugation. Again the supernatant was removed. The cell pellet was resuspended 
in 500 l 1xPBS. After pressing them through the filter caps of the FACS tubes, they 
were ready for analysis by FACS. 
 First, side scatter and forward scatter of untreated cells were measured and a gate 
wherein dead cells and doublets were excluded was applied. For this cell population, 
side scatter and GFP signal were measured. Like this, the threshold for GFP positive 
cells could be determined. A second gate above this threshold, which did not contain 
any cells, was applied.  
Subsequently, samples of cells infected with retrovirus were measured using these 
settings. The shift in GFP signal to higher intensities allowed determination of the 
percentage of GFP positive cells within the whole cell population. The data were 
analyzed using FlowJo Software. 
3.5.2 Cell cycle analysis 
PI (propidium iodide) is a fluorescent vital dye, which intercalates into double 
stranded nucleic acids. Because PI binds in proportion to the amount of DNA present 
in cells, it can be used to determine in which part of the cell cycle cells are. 
After detachment from culture plates and centrifugation of the cells as previously 
mentioned, the pellet was resuspended in 50 l of 1xPBS. While votexing, 1 ml of 
70% ethanol was added dropwise. Then the cells were stored at -20°C for one hour. 
After centrifugation at 4°C for 5 minutes at 1200 rpm, the supernatant was removed. 
The cells were washed once with 1xPBS. After another step of centrifugation and 
removal of supernatant, the pellet was resuspended in 500 l PI solution. The cell 
suspension was pressed through the cap of FACS tubes. Cell cycle distribution was 
measured by FACS and analyzed with FlowJo software. 
Methods  33 
 
Polo-like kinase 1 mediated phosphorylation regulates PAX3/FOXO1 in alveolar rhabdomyosarcoma 
3.6 In vitro kinase Assay 
All the steps mentioned below are described for one 15 cm plate. In order to have 
enough protein for subsequent mass spectrometrical analysis, everything was 
conducted simultaneously for 3 plates.  
3.6.1 Purification of PAX3/FOXO1 from HEK293T cells 
HEK293T cells were transfected with pCMV-NFlag-PAX3/FOXO1 plasmid DNA using 
the calcium phosphate technique. 40 hours post transfection, medium was removed 
and cells were washed with 10 ml 1xPBS. Cells were lysed with 2 ml lysis buffer and 
the lysate was collected. The lysate was pressed through a 25G needle several 
times. After 10 minutes incubation on ice, the lysate was centrifuged at 4°C for 10 
minutes at 10’000 rpm. The supernatant was collected. A mixture of 75 l 
Dynabeads, 0.4 ml PBS/0.02% Tween and 8 l (8 g) anti-Flag antibody was 
prepared in a 1.5 ml Eppendorf tube and incubated for 10 minutes at rotation. 
Afterwards, the tube was put in a Dyna-Mag magnetic concentrator rack and 
supernatant was removed. After washing with 2 ml PBS/0.02% Tween, the beads 
were resuspended in 1ml lysis buffer and distributed into low binding tubes. Again, 
the supernatant was removed. 2 ml supernatant of lysate after centrifugation were 
added and incubated at 4°C for 1 hour at rotation. After washing once with 2 ml lysis 
buffer and three times with 2 ml wash buffer, the beads were transferred to a new 1.5 
ml Eppendorf tube. 
3.6.2 CIP treatment 
100 l of CIP 1x reaction buffer and 4 l (80 units) CIP enzyme were added to the 
beads and incubated for 1 hour at 37°C while shaking. 1 l of CIP enzyme was 
added again followed by another 30 minutes of incubation. Afterwards, the tube was 
put in a Dyna-Mag magnetic concentrator rack and supernatant was removed. The 
beads were washed twice with lysis buffer and twice with wash buffer. Then the 
supernatant was removed. 
3.6.3 In vitro phosphorylation 
The dynabeads of 3 plates were combined (yielding approximately 2.5 g 
PAX3/FOXO1 protein, estimated in previous experiments by Verena Thalhammer) 
and 20 l of the following reaction mix was added. 
Table 20: reaction mix for in vitro phosphorylation 
Component Amount 
5x kinase buffer 8 l 
ATP 10mM 0.8 l 
PLK1 1.22 l (500 ng) 
H2O 29.98 l 
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The reaction mix was then incubated at 30°C for 30 minutes while shaking. 13.5 l of 
4x LDS+DTT was added and incubated for 5 minutes at 70°C to elute the 
phosphorylated protein. The supernatant was collected. Proteins were separated by 
gel electrophoresis. Subsequent in gel digestion with Trypsin and Chymotrypsin, 
mass spectrometry (Velos), and data analysis (mascot software) was performed by 
Dr. Laura Lopez. 
The working procedure of the in vitro kinase assay is summarized in Fig. 14. 
 
 
Figure 14: Work flow chart for purification of PAX3/FOXO1-NFlag from HEK293T cells and subsequent in 
vitro kinase assay 
 
3.6.4 Purification of PAX3/FOXO1 from bacteria 
BL21-CodonPlus (DE3)-RIL E.coli are bacteria containing a plasmid encoding for 
special t-RNAs that carries a chloramphenicol resistance gene, which allows 
expression of eukaryotic proteins containing rare codons. 
PAX3/FOXO1 wt was subcloned from the pMSCV-P3F-IRES-GFP plasmid into 
pTXB1 expression vector, in which it is C-terminally fused to an intein/chitin-binding 
domain, using the In-Fusion HD cloning protocol. This allows purification of full-length 
protein by affinity chromatography (Fig. 15). The vector is inducible by IPTG and 
carries an ampicillin resistance gene.  
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Figure 15: Purification of PAX3/FOXO1 from bacteria  
A) Schematic representation of affinity chromatography procedure B) Plasmid construct for expression in bacteria 
and subsequent isolation on a chitin beads column 
 
Bacteria were transformed by electroporation (kind help of Stefano Ferrari) and 
plated on LB agar plates containing 150 g/ml ampicillin and 25 g/ml 
chloramphenicol. The next day, colonies were picked to inoculate a 10 ml culture of 
LB medium with 150 g/ml ampicillin and 25 g/ml chloramphenicol. This inoculum 
was incubated for 6 hours at 37°C. With these 10 ml, a 1 L culture was inoculated. 
Bacterial growth was monitored by measuring OD600nm every 30 minutes. When 
the culture reached OD600nm=0.3, IPTG was added to a final concentration of 0.2 
mM and the incubator was put to 18°C. The culture was let to grow overnight.  
The following day, bacteria were pelleted by centrifugation at 4000rpm for 15 minutes 
at 4°C. After washing with 150 ml of 1xPBS and another round of centrifugation, the 
pellets were resuspended in 25 ml of pre-chilled (4°C) CH buffer with PMSF (0.1 mM) 
and complete protease inhibitor and put on ice. The bacterial suspension was 
sonicated at maximum power for 30 seconds followed by a 1 minute incubation time 
on ice. This cycle was repeated 4 times. Again PMSF was added. The sonicated 
bacteria were centrifuged at 18000 rpm for 45 minutes at 4°C. The supernatant was 
collected and again PMSF was added.  
All further steps were performed in a cold room at 4°C. The column, containing 2 ml 
of chitin-beads suspension, was equilibrated by passing 10 ml of CH buffer by 
gravity. The 25 ml of collected supernatant were loaded onto the column and let to 
flow slowly. Then the column was washed with 30 ml CH buffer with PMSF. The 
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column was closed and 2ml of CH buffer with 30 mM DTT were poured into it. The 
beads were resuspended and incubated overnight.  
The next day, the column was opened again and 2 fractions of 1 ml were recovered. 
After adding another 10 ml of CH buffer with 30 mM DTT, 10 more fractions of 1 ml 
were recovered. 10 l of the first two fractions, of the supernatant after centrifugation, 
and of the flow through after loading to the column were used for analysis by Westen 
blot.  
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4 RESULTS 
4.1 Validation of PLK1 knockdown experiments 
To examine whether PLK1 is able to regulate the transcriptional activity of 
PAX3/FOXO1, silencing of PLK1 was performed in different aRMS cell lines. For this 
purpose, siRNA technique was applied. It was already shown that knockdown of 
PLK1 with s1341 siRNA led to a decrease of expression of PAX3/FOXO1 target 
genes in different aRMS cell lines. Previous experiments with 8 nM of s1341 showed 
efficient knockdown (around 80% reduction of PLK1 mRNA expression) without 
inducing a cell cycle arrest or degradation of PAX3/FOXO1. Increased siRNA 
concentrations (25 nM) led to a G2/M arrest and degradation of PAX3/FOXO1 
protein. These findings suggested a direct effect of PLK1 phosphorylation on 
PAX3/FOXO1 transcriptional activity. Here, we wanted to validate this finding using a 
second siRNA. Different aRMS cells were incubated with scrambled siRNA as a 
control and with the second PLK1 specific siRNA (s449). I evaluated several 
conditions in a range of 2-8 nM (Table 1) to compare their knockdown efficiencies. 
Further I determined the effect of PLK1 silencing on PAX3/FOXO1 target gene 
expression. This was done by qRT-PCR (Taqman). mRNA expression levels were 
compared to scrambled siRNA treatment. 
4.1.1 PLK1 knockdown in RMS13 cells induces reduction in PAX3/FOXO1 
target gene expression 
 
Table 1: Summary of tested PLK1 knockdown conditions with reduction of PLK1 mRNA expression 
shown in brackets 
Rh3 Rh4 RMS13 RMS 
48h  48h 72h 48h 72h 48h 72h 
5 nM (70%) 
 
5 nM (77%) 
4 nM (63%) 
2 nM (53%) 
 
5 nM (63%) 
 
5 nM (66%) 
8 nM (78%) 
 
5 nM (63%) 5 nM (71%) 
8 nM (n.d.) 
5 nM (30%) 
n.d.: not determined (high toxicity) 
 
In general, Knockdown efficiencies were the highest in RMS13 cells using 8nM 
siRNA for 48 hours (around 80% reduction of PLK1 mRNA expression) (Table 1). In 
other cell lines, high toxicity was observed compared to RMS13 cells (judged by eye 
under light microscope). Relatively efficient knockdown of PLK1 in the other cell lines 
with different concentrations (despite 2 nM) of siRNA for 48hours was observed 
(around 60-70% reduction of PLK1 mRNA expression). Knockdowns were less 
efficient if cells were incubated for 72 hours (Table 1). Using 8 nM of siRNA for 48 
hours in RMS 13 cells, PAX3/FOXO1 target gene expression was downregulated. 
This finding could also be reproduced using the same conditions. FGFR4 expression 
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was reduced by approximately 10%. AP2beta expression was downregulated by 
roughly 26%, CDH3 by 22% (high variability) and PIPOX by 25%. The differentiation 
marker MYL1 was upregulated by 181% upon PLK1 knockdown (Fig. 1), 
demonstrating the relief from the block of differentiation normally found in aRMS 
cells. However, no effect on PAX3/FOXO1 target gene expression was found in other 
cell lines. Also incubation for 72 hours in these cells did not change this fact. Minor 
downregulation of few PAX3/FOXO1 target genes in RMS and Rh4 cells using 5nM 
or 4nM for 48 hours respectively could not be reproduced (data not shown). A 
possible explanation why I was not able to detect an effect on PAX3/FOXO1 target 
genes in other cells could be that other PLK isoforms are compensating for PLK1 
knockdown. Indeed, experiments of Verena Thalhammer showed that double 
knockdown of PLK1 and PLK2 or PLK4, could enhance the effect on PAX3/FOXO1 
target gene donwregulation (data not shown). 
 
Figure 1: PLK1 knockdown reduces PAX3/FOXO1 target gene expression in RMS13 cells 
TaqMan mRNA expression analysis of PAX3/FOXO1, PLK1 and PAX3/FOXO1 target genes after knockdown of 
PLK1 relative to scrambled siRNA treatment for 48 hours; FGFR4: Fibroblast growth factor receptor 4, AP2beta: 
activating enhancer binding protein 2 beta, CDH3: P-cadherin, MYL1: myosin light chain 1, PIPOX: pipecolic acid 
oxidase; biological replicates of two independent experiments. Error bars represent standard deviations 
 
4.1.2 PLK1 knockdown in RMS13 cells induces degradation of PAX3/FOXO1 
and G2/M arrest 
Because we were able to detect PAX3/FOXO1 target gene downregulation in RMS13 
cells only, we used this cell line for further experiments. To investigate if PLK1 
knockdown has an effect on protein levels of PAX3/FOXO1 itself, we performed 
Western blot analysis with protein samples isolated 48 hours after treatment with 8 
nM siRNA. To evaluate if PLK1 knockdown induces a cell cycle arrest, PI staining of 
cells was performed followed by FACS analysis after 8 nM siRNA treatment for 48 
hours.  
Interestingly, we found a strong degradation of PAX3/FOXO1 protein (Fig. 2A) and 
cell cycle arrest (Fig. 2B) in RMS13 cells (80% of cells in G2) after PLK1 knockdown 
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with 8 nM s449 (data provided by Verena Thalhammer). This effect was already 
observed previously with 25 nM of s1341. 
 
Figure 2: Effects of PLK1 silencing in RMS13 cells 
A) Western blot analysis showing PAX3/FOXO1 and PLK1 protein levels after PLK1 knockdown in RMS13 cells 
with actin as loading control B) Cell cycle distribution after PLK1 knockdown in RMS13 cells measured by PI 
staining followed by FACS 
 
To summarize, we were able to confirm that upon silencing of PLK1 in RMS13 cells, 
PAX3/FOXO1 target genes are downregulated. In other words, we could reproduce 
the findings of previous experiments with s1341 using another siRNA. This suggests 
that PLK1 is indeed able to influence the transcriptional activity of PAX3/FOXO1. 
Further, we observed that PLK1 knockdown causes a cell cycle arrest and reduces 
cell viability in aRMS cells. Because of the degradation of PAX3/FOXO1 protein after 
PLK1 knockdown, we suggest that PLK1 might have a stabilizing effect on 
PAX3/FOXO1. 
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4.2 Identification of phosphorylation sites in PAX3/FOXO1 by in 
vitro kinase assay and mass spectrometry 
To investigate if PLK1 is able to directly phosphorylate PAX3/FOXO1 we performed 
an in vitro kinase assay with subsequent mass spectrometrical analysis. Using this 
approach we wanted to identify possible PLK1 phosphorylation sites within 
PAX3/FOXO1. 
For this we transfected HEK293T cells with pCMV plasmid vector containing N-
terminally Flag tagged PAX3/FOXO1 using the calcium phosphate technique. 
PAX3/FOXO1 was then purified by affinity chromatography. Afterwards, we 
dephosphorylated PAX3/FOXO1 with calf intestinal phosphatase (CIP) and incubated 
PAX3/FOXO1 with recombinant PLK1. Because previous experiments with 2500 or 
2000 ng of PLK1 suggested that unspecific phosphorylation might have occurred, we 
now used only 500 ng of recombinant kinase instead. After gel electrophoresis, 
PAX3/FOXO1 was digested in gel with Trypsin or Chymotrypsin. The samples were 
analyzed by mass spectrometry using the Velos Mass Spectrometer. In-gel digestion, 
mass spectrometry and data analysis (mascot software) was performed by Dr. Laura 
Lopez. 
4.2.1 PLK1 phosphorylates PAX3/FOXO1 at several sites in vitro 
We were able to identify four different peptides within PAX3/FOXO1, which are 
potentially phosphorylated by PLK1 in vitro. Each peptide was only identified once in 
three different runs using the same conditions (500 ng PLK1). However, three of 
these peptides were previously found phosphorylated with 2500 or 2000 ng of PLK1 
used in the kinase assay. Only runs where peptides were not found phosphorylated 
in CIP treated samples were considered. Interestingly, one peptide (T497-R508) was 
often not dephosphorylated by CIP treatment but when it was, it was always found 
phosphorylated (Table 2). To determine which sites within these peptides are most 
probably phosphorylated we used two criteria. The firs one were prediction values 
gathered by software analysis. Secondly, we checked the peptides for PLK1 
consensus sequences [78, 79]. A site for witch both of those criteria were fulfilled 
was S503. Mass spectrometry data for this peptide are shown in Figure 3. Coverage 
of the protein was around 80% when combining the Trypsin and Chymotrypsin 
digested samples (Fig. 4A). In total we considered six potential PLK1 
phosphorylation sites. The sites with the corresponding position in the amino acid 
sequence of PAX3/FOXO1 were S30, S389, S393, S399, S402 and S503 (Fig. 4A). 
S393, S399, S402 and S503 lie within the FOXO1 part of the fusion protein (Fig. 4B).  
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Table 2: Phospho-peptides within PAX3/FOXO1 identified after in vitro phosphorylation by PLK1 
 
pep-score: value for goodness of protein sequence match 
pep_expect: probability that mass change compared to reference is a result of coincidence 
 
 
 
Figure 3: Representative MS spectra of the peptide containing S503 
Flag-Pax3FOXO1 was overexpressed in HEK293T cells, immunoprecipitated using anti Flag antibody, 
dephosphorylated in vitro by CIP treatment and digested with trypsin for MS analysis. A) Dephosphorylated 
peptide showing the ion at 620 m/z representative of unmodified S503. B) Peptide after PLK1 in vitro kinase 
assay showing the shift of the ion to 700 m/z indicating phosphorylation of S503, however, phosphorylation of 
T504 instead, cannot be discarded by the MS result. 
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Figure 4: Identification of potential PLK1 phosphorylation sites within PAX3/FOXO1 
A) Aminoacid sequence of PAX3/FOXO1 with identified phosho-peptides (black bars) and potential 
phosphorylation sites (green circles) by mass spectrometry after in vitro phosphorylation by PLK1. Covered 
sequences are shown in red B) Schematic representation of PAX3/FOXO1 with potential PLK1 phosphosites 
depicted in green 
 
Because there is also a phospho-antibody available against pS322 in FOXO1 
(corresponding to pS503 in PAX3/FOXO1), we also tested by Western blot if this site 
is phosphorylated after in vitro phosphorylation by PLK1. S322 is described in the 
literature as a site for CK1 phosphorylation, which mediates nuclear export of FOXO1 
[60]. For this we analyzed samples of PAX3/FOXO1 after the in vitro phosphorylation 
with PLK1 or CK1 and a sample of PAX3/FOXO1 after CIP treatment as a control 
and performed Western blot analysis. This experiment demonstrated that PLK1 as 
well as CK1 is able to phosphorylate PAX3/FOXO1 in vitro (Fig. 5). This 
phosphorylation was not detected in the CIP treated sample. This result confirmed 
our findings from the mass spectrometrical analysis, demonstrating that PLK1 can 
phosphorylate PAX3/FOXO1 at S503.  
 
Figure 5: PLK1 phosphorylates PAX3/FOXO1 at S503 in vitro 
Western blot of PAX3/FOXO1 after in vitro phosphorylation by CK1 or PLK1 and after dephosphorylation by CIP 
as a control; P3F pS503: Anti-FOXO1 (p322), P3F: Anti-FOXO1 
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4.2.2 Purification of PAX3/FOXO1 from bacteria 
Because dephosphorylation of purified protein was not 100% successful, we decided 
to express PAX3/FOXO1 in bacteria, since they lack most of the eukaryotic 
posttranslational machinery and therefore PAX3/FOXO1 will not be phosphorylated. 
For this, we transformed BL21-CodonPlus (DE3)-RIL E.coli with PAX3/FOXO1, fused 
to an intein/chitin-binding domain (for plasmid construct see material and methods) 
and tried to recover the protein by affinity chromatography. To detect if PAX3/FOXO1 
protein was expressed and also properly purified, we performed Western blot 
analysis. We loaded 10l of the first two recovered fractions after elution from the 
chitin beads column. Additionally, 10l of a control sample after lyisis of the bacteria 
and 10l of a control sample of the flow through after loading the column were 
loaded.  
As it turned out, no protein was eluted from the column (Fig. 6). However, the 
bacterial lysate contained high amount of protein, demonstrating that induction of 
expression by IPTG worked. The problem was that the flow through after loading of 
the column also showed high amount of protein, indicating that the binding to the 
chitin beads was compromised. The whole intein/chitin-binding domain has an 
approximate size of 30kDa. However, no shift correlating with this size was observed. 
In general, PAX3/FOXO1 was running at the level of the wild type protein (100 kDa) 
on this blot (Fig. 6). 
 
Figure 6: Unsuccessful purification of PAX3/FOXO1 from BL21-CodonPlus (DE3)-RIL E.coli 
Western blot with samples of the two first fractions after elution from the chitin beads column (Fractions 1 and 2) 
and the two control samples; Control1: bacterial lysate after centrifugation, Control 2: flow through after loading of 
the column 
 
Detailed sequence analysis revealed that an insertion of two base pairs at the 
beginning of the intein tag resulted in frame shift. As a consequence of this, a stop-
codon was generated shortly after the beginning of the tag, which explains why 
PAX3/FOXO1 did not bind to the chitin column and also why we were not able to see 
a shift in size compared to wild type PAX3/FOXO1 protein on the blot.  
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4.3 Retroviral transduction of RD cells is a suitable tool for testing 
PAX3/FOXO1 activity 
I wanted to investigate if any of the identified phosphosites of PAX3/FOXO1 indeed 
have an influence on the transcriptional activity of PAX3/FOXO1. Since I aimed to 
test a bigger subset of PAX3/FOXO1 target genes, a novel read-out system was 
needed. Because transient transfection of target cells (Rh4, Rh4 with AP2beta 
luciferase reporter and HEK293T) with PAX3/FOXO1 did not have any effect on 
target gene expression levels in previous experiments, we decided to use a retroviral 
system instead. I transduced different target cells including human and mouse 
mesenchymal stem cells (MSCs), primary human MSCs and RD, an embryonal 
rhabdomyosarcoma cell line not expressing PAX3/FOXO1. HS5 is a human cell line 
derived from bone marrow tissue and is routinely used for co-culture with 
hematopoietic progenitor cells. This cell line was used as a first model to infect 
human mesenchymal stem cells. The decision to use mesenchymal stem cells was 
based on the fact that they might be the cells of origin for RMS and therefore are 
thought to provide an ideal cellular background in this context. Previous publications 
showed that retroviral transduction of mMSC and RD cells with PAX3/FOXO1 is 
possible and transduction of PAX3/FOXO1 induces gradual target gene expression 
in those cell lines [80, 81].  
4.3.1 RD cells can be efficiently transduced with PAX3/FOXO1 
First of all I optimized transduction efficiencies since this is a prerequisite for inducing 
PAX3/FOXO1 target gene expression, which is important for a system in which 
PAX3/FOXO1 activity will be tested. I was provided with the pMSCV-PAX3/FOXO1-
IRES-GFP retroviral plasmid by Elisa Zimmermann. This vector allows production of 
retroviral particles containing PAX3/FOXO1 when transfected in an appropriate 
packaging cell line. An advantage of this plasmid is that it encodes for GFP and 
therefore allows monitoring how many cells are infected by FACS. I used two 
different packaging cell lines, which have different envelope proteins and therefore 
different tropisms. Also I tried different infection protocols. Cells were either infected 
by just incubating target cells with virus supernatant overnight (once or twice) or by 
one hour centrifugation of target cells with virus supernatant (Table 3). As a control I 
infected target cells with virus produced with empty retroviral vector (GFP). Infection 
efficiencies were measured 96 hours after infection of target cells by FACS. The data 
were then analyzed with FlowJo software (example see Fig. 7).  
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Table 3: Overview of tested infection conditions showing percentages of GFP positive cells 96 hours post 
transduction 
 
GFP: transduction with empty vector 
P3F wt: transduction with PAX3/FOXO1 wild type 
n.d. : not determined 
 
Evaluation of percentages of GFP positive cells transduced with empty vector led to 
the following conclusions. In general, transduction was more efficient when virus was 
produced with 293 GPG cells (Table 3). Additionally, infection was better when I 
infected target cells by one hour centrifugation compared to overnight incubation. 
Also two subsequent overnight incubations with virus supernatant did not improve 
infection efficiencies (Table 3). Interestingly, virus produced with phoenix ampho 
packaging cells was more infectious on mouse cell lines than on human cell lines. 
One hour centrifugation with virus produced in phoenix ampho cells led to an 
infection rate in mMSC cells of 44.7%, whereas only 8.5% of HS5 cells were infected 
(Table 3). On the other hand, virus produced with 293 GPG packaging cells was 
highly infectious for mMSCs (87% GFP positive) and HS5 (69.4% GFP positive). 
Additionally, virus produced in 293 GPG cells was much more infectious in general 
(Table 3). This is why I decided to infect RD, primary hMSC, Rh4 and HEK293T cells 
by one hour centrifugation with virus produced in 293 GPG packaging cells. Primary 
hMSCs were much more difficult to infect than all other cell lines (Table 3). I was able 
to reach the highest infection rates in RD cells, where over 90% of cells were GFP 
positive (Table 3).  
These data show that virus produced in different packaging cell lines have different 
tropisms due to their envelope proteins. For my purpose, I could reach higher 
infection efficiencies when virus was produced with 293 GPG cells and infection was 
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performed by one hour centrifugation. Therefore, all further infections were 
performed with virus produced in 293 GPG cells by centrifugation for one hour. 
I could observe that the GFP positive cells transduced with empty vector showed 
higher fluorescence intensities than GFP positive cells infected with PAX3/FOXO1 
expressing virus (Fig. 7A/B). The reason for this is that the translation of the second 
gene in the cassette is significantly lower than that of the first one [82]. Since 
PAX3/FOXO1 is the first gene in the vector before the IRES element, downstream 
GFP expression will be lower.  
 
Figure 7: Infection of RD cells with viruses produced in 293 GPG packaging cells by one hour 
centrifugation yields high transduction efficiencies. 
FACS analysis performed 96h post infection; A) FACS output data: untreated cells were used for gating (top row), 
GFP: empty vector control retrovirus infected cells (middle row), P3F wt: PAX3/FOXO1 wild type retrovirus 
infected cells, black: total of counted cells, red: P1= viable single cells, green: P2= GFP positive cells B) Same 
dataset analyzed with FlowJo software: after refinement of gating, only P1 subpopulations were analyzed 
 
4.3.2 Transduction with PAX3/FOXO1 induces target gene expression in RD 
cells as well as in other cell lines 
To identify target genes of PAX3/FOXO1, which are upregulated upon transduction 
with P3F wt, I performed qRT-PCR analysis 96 hours post transduction. Expression 
of target genes were compared to empty vector transduced cells (GFP). As target 
genes, I investigated all genes previously identified from knockdown studies, as well 
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as some additional target genes reported to be upregulated in RD cells upon 
transduction with PAX3/FOXO1 [80]. 
 
Figure 8: Transduction with PAX3/FOXO1 induces target gene expression in different cell lines 
TaqMan mRNA expression analysis of PAX3/FOXO1 and different target genes in various cell lines measured 
96h after transduction with PAX3/FOXO1 retrovirus. Relative mRNA expression levels compared to empty vector 
retrovirus infected cells; FGFR4: fibroblast growth factor receptor 4, MYL1: myosin light chain 1, MYCN: N-MYC 
proto oncogene protein, PIPOX: pipecolic acid oxidase, MYOD: myoblast determination protein 1, DUSP4: dual 
specific phosphatase 4, TNNC2: troponin C type 2, MET: hepatocyte growth factor receptor, PRKAR2B: cAMP-
dependent protein kinase type II-beta, POU4F1: POU class 4 homeobox 1, AP2beta: activating enhancer binding 
protein 2 beta, CB1: cannabinoid receptor 1, CDH3: cadherin 3. Error bars represent standard deviations of three 
independent biological replicates 
 
Two types of target cells, which showed PAX3/FOXO1 target gene induction, were 
RD and primary hMSCs. RD cells showed minor upregulation of FGFR4 expression 
(153%), intermediate upregulation of MYOD (217%), MET (264%), PRKAR2B 
(259%) and POU4F (250%) expression. Minor downregulation was observed for 
MYL1 (65%), DUSP4 (69%) and TNNC2 (74%) expression (Fig. 8). This was 
expected since MYL1 and TNNC2 are differentiation markers and PAX3/FOXO1 is 
known to inhibit differentiation. DUSP4 was already described to be downregulated 
upon transduction of RD cells with PAX3/FOXO1 [80]. Strong upregulation of MYCN 
(440%) and PIPOX (1115%) expression was detected (Fig. 8). All target genes were 
already expressed in the empty vector retrovirus infected control samples (GFP). 
PAX3/FOXO1 expression in GFP samples were at assay background levels 
(detected in all experiments: ct36). Expression of the fusion protein was increased 
900 fold compared to control samples (Fig. 8). The finding of target gene induction in 
hMSCs was rather surprising because only 7.4% of cells were infected. 
Consequently, expression of the fusion protein was less strong than in RD cells (only 
20 fold increase compared to control). Nevertheless, strong upregulation (over 600% 
compared to control) of FGFR4, PIPOX, MYOD, TNNC2 and POU4F expression was 
detected (Fig. 8). All of these target genes except FGFR4 were not expressed in the 
empty vector transduced control samples (GFP). These two cell lines were therefore 
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considered to serve as possible systems for testing the activity of PAX3/FOXO1 
phosphomutants. Because primary hMSCs did grow very slowly and were difficult to 
infect, I focused on RD for all subsequent experiments. Additionally, I found target 
gene induction in HEK293T and Rh4 cell lines (Fig. 8). Although in these cell lines 
the most well characterized PAX3/FOXO1 target genes were upregulated upon 
infection with the fusion protein, they were not suitable for the testing of 
phosphomutants, because of high endogenous PAX3/FOXO1 expression in Rh4 and 
the lack of potentially important cellular background for PAX3/FOXO1 transcriptional 
activity in HEK293T.  
Taken together, I was able to induce PAX3/FOXO1 target gene expression by 
transduction with PAX3/FOXO1 wild type in RD cells in a reproducible manner. The 
percentage of upregulation of target genes in this cell line was suggested to provide 
a big enough window for the testing of phosphomutants. In addition, RD cells also 
express high amounts of PLK1, which is important as we are interested in PLK1 
dependent phosphorylation of PAX3/FOXO1 and its effect on transcriptional activity. 
4.3.3 Differences in activity between PAX3/FOXO1 wild type and PAX3/FOXO1 
phosphomutants are time point dependent 
To test whether I am able to detect differences in transcriptional activities between 
wild type PAX3/FOXO1 and the phosphomutant isoforms, I established a positive 
control, which is known to have less transcriptional activiy compared to 
PAX3/FOXO1 wild type. This phosphomutant control is the previously described 
mutant with six serines transformed into alanine (S187A, S193A, S197A, S201A, 
S205A, S209A), which lie between the homeodomain and the paired domain of 
PAX3 and is reported to have decreased DNA binding ability (P3F 6xA) [46]. To be 
able to produce virus with this mutant, I had to subclone it from the pcDNA3 vector 
into my pMSCV-IRES-GFP retroviral vector.  
To investigate if the differences in target gene expression between wild type 
PAX3/FOXO1 and the phosphomutant isoforms are time dependent and which time 
point should be used for testing phosphomutants, I performed a time course 
experiment. For this I transduced RD cells with PAX3/FOXO1 wild type, 
PAX3/FOXO1 6xA and empty vector virus (GFP) as a control. Analysis of gene 
expression was performed by qRT-PCR after 48, 96, 144 and 192 hours. I checked 
all upreglated target genes that I was able to identify upon PAX3/FOXO1 wild type 
transduction (FGFR4, MYCN, PIPOX, MYOD, PRKAR2B, MET and POU4F1) and 
only MYL1 as a downregulated target gene. 
It is important to mention that the mRNA expression levels of PAX3/FOXO1 itself 
were not exactly the same for P3F wt and P3F 6xA at 96 (30% less P3F 6xA) and 
144 (19% less P3F 6xA) hours post transduction (Fig. 9A). Apart from MET and 
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MYL1, all target genes showed lower expression upon transduction with P3F 6xA (at 
least after 96 hours). The differences of FGFR4 expression were minor (Fig. 9B). For 
MYCN, PIPOX, MYOD and PRKAR2B the expression levels peaked after 96 hours 
post infection. At this time point, also the differences between induced target gene 
expression of P3F wt and P3F 6xA were most pronounced. POU4F1 expression 
instead was highest after 48 hours and progressively decreased afterwards but still 
with less expression after transduction with P3F 6xA (Fig. 9B). The differences of 
target gene expressions did exceed the differences between P3F wt and P3F 6xA 
expression (strongest in MYCN and PIPOX). Additionally, differences in target gene 
expression could also be detected for time points with equal PAX3/FOXO1 
expression (Fig. 9A/B).  
 
Figure 9: Timecourse experiment of RD cells transduced with PAX3/FOXO1 wild type and PAX3/FOXO1 
6xA respectively  
A) TaqMan mRNA expression analysis of PAX3/FOXO1 6xA relative to PAX3/FOXO1 wild type in transduced 
cells B) TaqMan mRNA expression levels of PAX3/FOXO1 wild type and PAX3/FOXO1 6xA induced target genes 
relative to empty vector control; FGFR4: fibroblast growth factor receptor 4, MYL1: myosin light chain 1, MYCN: 
N-MYC proto oncogene protein, PIPOX: pipecolic acid oxidase, MYOD: myoblast determination protein 1, 
DUSP4: dual specific phosphatase 4, TNNC2: troponin C type 2, MET: hepatocyte growth factor receptor, 
PRKAR2B: cAMP-dependent protein kinase type II-beta, POU4F1: POU class 4 homeobox 1 
 
This time course experiment showed that differences between the activities of P3F wt 
and P3F 6xA after transduction are time dependent. The biggest difference in 
transcriptional activity was observed between 96 and 144 hours post transduction. 
On this basis, I decided to use 120 hours as the time point for the testing of all 
phosphomutants with MYCN, PIPOX, MYOD, PRKAR2B and POU4F1 as read-out 
target genes. FGFR4, MET and MYL 1 were neglected in subsequent experiments. 
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4.3.4 Positive controls show less activity than PAX3/FOXO1 wild type upon 
transduction of RD cells 120 hours after infection 
To confirm that differences between PAX3/FOXO1 wild type and positive controls 
can be detected in the same setting in which I wanted to test my phosphomutants, I 
infected RD cells with P3F wt, P3F 6xA, P3F G48S, P3F N269A and empty vector 
virus (GFP) as a control. The latter two mutants are DNA binding deficient mutants 
with muatated sites within the homeodomain (G48S) and the paired domain (N269A) 
of PAX3 [83]. Also these mutants were generated by subcloning from the pcDNA3 
vector into pMSCV-IRES-GFP retroviral vector.  
I analyzed target gene expression 120 hours after transduction by qRT-PCR and 
performed Western blot to quantify protein levels. Infection efficiencies were 
measured at the same time point in parallel by FACS.  
On mRNA level, the two DNA binding mutants were much higher expressed than 
P3F wt. P3F 6xA was approximately 10% less expressed than P3F wt (Fig. 10A). I 
found that PIPOX and MYOD expression was not increased by either infection with 
P3F G48S or P3F N269A virus compared to empty vector virus infected cells (Fig. 
10A). This suggests that binding of PAX3/FOXO1 to enhancer or promoter regions of 
these genes occurs through both the homeodomain and the paired domain of PAX3. 
On the other hand, expression levels of NMYC did not increase upon infection with 
P3F G48S virus compared to infection with empty vector virus, whereas P3F N269A 
infected cells showed increased expression of NMYC compared to empty vector 
infected cells (Fig. 10A). This suggests that binding of PAX3/FOXO1 to 
transcriptional regulatory elements of NMYC mainly involves the homeodomain. The 
same was true for PRKAR2B. The opposite effect was observed for POU4F1 
expression (Fig.10A), since binding of PAX3/FOXO1 to regulatory DNA sequences 
seems to be mediated mostly through the paired domain of PAX3. Most importantly, 
for every target gene at least one DNA binding mutant did not increase expression 
compared to empty vector control. An outlier in this context is PRKAR2B, expression 
of which was induced by both P3F G48S and P3F N269A. The latter even induced 
stronger expression than P3F wt (Fig. 10A). This fact leaves room for arguing that 
PRKAR2B might not be a direct target of PAX3/FOXO1. Finally, cells transduced with 
P3F 6xA virus displayed a reduced target gene expression profile compared to P3F 
wt infected cells. This reduction of target gene expression ranged from 20-40% 
between the target genes (Fig. 10A). I saw that infection efficiencies were very 
similar for P3F wt and P3F G48S, whereas P3F N269A virus infected roughly 10% 
more cells. P3F 6xA virus did infect approximately 10% less cells than did P3F wt 
virus (Fig. 10B). Interestingly, P3F 6xA was also expressed 10% less on mRNA level 
compared to P3F wt. Protein levels of P3F G48S and P3F N269A were much higher 
(2 fold more for P3F G48S and over 3 fold more for P3F N269A) than that of P3F wt 
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(Fig. 10C). This is probably because cells tend to tolerate higher amounts of inactive 
protein. Protein levels of P3F 6xA were slightly lower than P3F wt protein levels 
(around 25% less) (Fig. 10C). Because on mRNA level expression of both was 
approximately the same, an additional effect on protein stability besides the already 
described effect on DNA binding was taken into consideration. Preliminary data also 
suggest that this mutant might have reduced stability (Fig. 16A). However I cannot 
exclude that the effect on protein level is due to unequal infection rates.  
 
Figure 10: Transduction of RD cells with positive control PAX3/FOXO1 isoforms results in decreased 
target gene expression compared to PAX3/FOXO1 wild type  
A) TaqMan mRNA expression analysis of PAX3/FOXO1 and PAX3/FOXO1 target genes in RD cells 120h after 
transduction with either PAX3/FOXO1 wild type or PAX3/FOXO1 6xA, expression levels relative to PAX3FOXO1 
wild type. Biological replicates of 2 experiments conducted with same virus supernatants. Error bars represent 
standard deviations B) FACS analysis was used to assess percentages of GFP positive cells for each 
transduction procedure 120h after infection C) Western blot analysis showing PAX3/FOXO1 protein levels 120h 
after transduction 
 
Alltogether, these findings suggest that with this retroviral approach, I am technically 
able to see differences in PAX3/FOXO1 target gene expression between wild type 
PAX3/FOXO1 and PAX3/FOXO1 phosphomutants with an effect on transcriptional 
activity.  
 
4.4 Testing the activity of PAX3/FOXO1 phosphomutants by 
transduction of RD cells 
Phosphomutants of the sites identified by mass spectrometry after in vitro 
phosphorylation with PLK1 were generated by site directed mutagenesis (Table 4). 
Additionally to these mutants, I generated phosphomutants of other sites. One of 
these sites was T31, which was found to be phosphorylated in vitro by CDK1 and is 
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located within a polobox-binding motif potentially priming for PLK1 binding. The T31A 
and T31D phosphomutants were generated by site directed mutagenesis (Table 4). 
Two single mutants with sites of the P3F 6xA mutant were also tested (S201A and 
S205A). These mutants were subcloned from the pcDNA3 vector into pMSCV-IRES-
GFP retroviral vector (Table 4). Also S399 was tested as a single mutant. Another 
site, which was predicted to be phosphorylated by PLK1 was S442. Also these 
mutants were generated by site directed mutagenesis (Table 4).  
Table 4: Overview of generated PAX3/FOXO1 mutants 
PLK1 sites 
(MS) 
PLK1 
predicted 
Potential PLK1 
binding site 
Known 
phospho sites 
DNA binding 
mutants 
S30A S442A T31A S201A G48S * 
S389/393A S510A ** T31D S205A N269A * 
S399/402A   6xA *  
S503A      
S399A     
* : positive controls for measuring transcriptional activity (see sections 4.3.3 and 4.3.4) 
** : only used for testing stability (see section 4.6.1) 
 
In general, alanine mutants can no longer be phosphorylated. Should 
phosphorylation of one of those sites have an influence on the transcriptional activity 
of PAX3/FOXO1, reduced activity of the alanine mutants is expected. In other words, 
PAX3/FOXO1 alanine phosphomutants should not induce target genes as strong as 
PAX3/FOXO1 wild type. In contrast, aspartic acid phosphomutants mimic 
phosphorylation at this site and should rescue the decrease in activity of the alanine 
mutants. 
To investigate if any of these mutations affect transcriptional activity of the fusion 
protein, I transduced RD cells with the phosphomutant isoforms of P3F, P3F wt and 
empty vector retrovirus (GFP) as controls. 120 hours after infection I measured target 
gene expression by qRT-PCR. Infection efficiency was also measured 120 hours 
post transduction by FACS as well as Western blot analysis to quantify protein levels. 
Protein levels were quantified by densitometry using ImageJ software. 
4.4.1 Phosphomutants of PLK1 sites do not display reduced activity but 
S503A might be less stable 
On mRNA level, expression of PAX3/FOXO1 was higher for all phosphomutants 
compared to P3F wt (Fig. 11A). For P3F S399/402A, expression could not be 
detected with breakpoint specific PAX3/FOXO1 gene expression assay and had to 
be measured using a PAX3 gene expression assay (Fig. 11A). Probably, binding of 
the TaqMan probe or of the primers to the target sequence was affected by the 
mutations. Target gene expression was not reduced by any of the phosphomutants 
tested compared to wild type PAX3/FOXO1 in this setting. Interestingly, quite the 
contrary seemed to be the case. Target genes were a little higher expressed in 
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phosphomutant P3F transduced cells than in P3F transduced cells (Fig. 11A). This 
might be caused by the fact that higher amounts of infectious viral particles were 
used, resulting in higher infection efficiencies, since I did not titrate the viral stocks. 
Indeed, infection efficiencies were not the same for the different viruses. Compared 
to P3F wt, all phosphomutant viruses were more infectious. The only exception was 
P3F S30A virus, which infected almost same amounts of cells as did P3F wt virus. 
For the other phosphomutants, infection efficiencies were 15-20% higher compared 
to P3F wt virus (Fig. 11B). Protein levels of P3F S389/399A and P3F S399/402A 
were much higher than that of P3F wt (Fig. 11C), as could be expected from the 
higher infection rates. P3F S30A protein amounts were comparable to those of P3F 
wt (Fig. 11C), probably also because infection efficiencies were similar. Surprisingly, 
protein levels of P3F S503A were also in the range of P3F wt although infection was 
much more efficient with P3F S503A and also mRNA expression levels were much 
higher compared to P3F wt (Fig. 11A/B/C). One possible reason for this observation 
could be that P3F S503A protein is less stable than P3F wt.  
 
Figure 11: Testing the transcriptional activity of PAX3/FOXO1 phosphomutants (sites identified with mass 
spectrometry after in vitro phosphorylation by PLK1) by retroviral transduction of RD cells 
A) TaqMan mRNA expression analysis of PAX3/FOXO1 and PAX3/FOXO1 target genes in RD cells 120h after 
transduction with either PAX3/FOXO1 wild type or PAX3/FOXO1 phosphomutants, expression levels relative to 
PAX3FOXO1 wild type. Biological replicates of two indepentdent experiments. Error bars represent standard 
deviations B) FACS analysis was used to assess percentages of GFP positive cells for each transduction 
procedure 120h after infection C) Western blot analysis showing PAX3/FOXO1 protein levels 120h after 
transduction, densitometrical analysis performed with ImageJ software showing protein levels relative to 
PAX3/FOXO1 wild type 
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4.4.2 Additional phosphomutants also do not display reduced activity 
All additional phosphomutants were also more expressed on mRNA level than was 
P3F wt (Fig. 12A). Also here no phosphomutant with reduced transcriptional activity 
compared to wild type PAX3/FOXO1 could be identified. All phosphomutants induced 
higher target gene expression than did P3F wt (Fig. 12A). With the exception of P3F 
S399A, all phosphomutant viruses were more infectious than P3F wt virus (Fig. 12B). 
Interestingly, also this phosphomutant was higher expressed than P3F wt like all 
other phosphomutants. On protein level, all phosphomutants showed higher 
expression than did P3F wt (Fig. 12C). Again, as it was mentioned previously, 
differences in target gene expression between P3F wt and the P3F phosphomutants 
are likely due to differences in infection efficiencies.
 
Figure 12: Testing the transcriptional activity of additional PAX3/FOXO1 phosphomutants  
A) TaqMan mRNA expression analysis of PAX3/FOXO1 and PAX3/FOXO1 target genes in RD cells 120h after 
transduction with either PAX3/FOXO1 wild type or PAX3/FOXO1 phosphomutants, expression levels relative to 
PAX3FOXO1 wild type. B) FACS analysis was used to assess percentages of GFP positive cells for each 
transduction procedure 120h after infection C) Western blot analysis showing PAX3/FOXO1 protein levels 120h 
after transduction, densitometrical analysis performed with ImageJ software showing protein levels relative to 
PAX3/FOXO1 wild type 
 
Taken together, I was not able to identify a PAX3/FOXO1 phosphomutant with 
reduced transcriptional activity. As a remark I would like to mention that this activity 
read-out system for testing of PAX3/FOXO1 phosphomutants remains to be 
improved (see discussion). As time was a limiting factor for my work in the laboratory, 
I regret that I have not been able to make these refinements. However, some results 
might indicate that P3F S503A has decreased protein stability and therefore might be 
less active. 
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4.5 Cycloheximide treatment of transfected RD cells is an 
instrument to measure PAX3/FOXO1 stability 
We found that phosphorylation by PLK1 might stabilize PAX3/FOXO1 (see section 
4.1.2) and my experiments gave additional hints that some phosphomutants 
(especially P3F S503A) might be less stable (see section 4.4.1). For this reason we 
wanted to directly investigate if any P3F phospomutant of potential PLK1 sites is less 
stable than P3F wt. Towards this end, we treated cells with cycloheximide (CHX) and 
monitored protein levels after treatment.  
4.5.1 PAX3/FOXO1 is degraded in RD cells after cycloheximide treatment 
First, I investigated whether I can detect degradation of P3F wt upon CHX treatment. 
I used RD cells for these experiments since they also were my choice for testing the 
activity before. This decision was based on the same arguments mentioned 
previously. Additionally, I chose C2C12 cells, which is a mouse myoblast cell line, 
because it was already published that PAX3/FOXO1 is degraded in C2C12 cells 
treated with 5 M CHX [84]. Since I did not want to express high amounts of protein, I 
only transfected cells overnight with 1 g of pMSCV-PAX3/FOXO1-IRES-GFP 
plasmid DNA using the JetPrime protocol in order to be able to see degradation after 
short periods of CHX exposure. I treated cells with 10 g/ml CHX (35 M) or DMSO 
for 3, 6 and 24 hours. Protein was isolated at the indicated time points and analyzed 
by Western blot. Quantification of protein levels was performed with ImageJ software, 
corrected for loading using GAPDH and normalized to the 0h time point. As a control 
for efficiency of CHX treatment Cyclin B1 protein levels were monitored, which is 
known to be rapidly degraded. This is because Cyclin B1 protein levels cannot be 
replenished after anaphase under efficient CHX treatment.  
As far as toxicity is concerned, RD cells were more resistant to the treatment, 
whereas C2C12 cells did not seem to tolerate such high doses of CHX equally well 
(judged by eye under light microscope). A first observation was that RD cells 
expressed lower amounts of protein compared to C2C12 cells for all time points (Fig. 
13A). Probably these cells are more efficiently transfected or have a higher synthesis 
rate in general. Importantly, CHX treatment seemed to be more efficient in RD cells, 
as Cyclin B1 protein levels decreased faster (Fig. 13A/B). As a consequence, protein 
levels of PAX3/FOXO1 were decreased more in RD (around 50%) than in C2C12 
cells (around 15%) after 6 hours of CHX treatment (Fig 13A/B). Exposure of cells to 
CHX for 24h was already too long, at least for C2C12 cells, because principally all 
cells died already. I selected the 6 hours treatment with 10 g/ml CHX in RD cells for 
further experiments, because I was able to detect sufficient degradation of 
PAX3/FOXO1 at this time point and concentration.  
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Figure 13: PAX3/FOXO1 gets degraded after cycloheximide treatment  
A) Western blots showing PAX3/FOXO1 wild type protein levels after overnight transfection (0h) and 3h, 6h, 24h 
cycloheximide treatment (10g/ml) in RD and C2C12 cells. Cyclin B1 protein levels are shown for each time point 
too as an indicator of effective cycloheximide treatment. GAPDH is shown as loading control B) Relative 
quantification of PAX3/FOXO1 and Cyclin B1 protein levels was performed with ImageJ software. Protein levels 
are relative to the 0h time point  
 
4.5.2 PAX3/FOXO1 wild type is less expressed in RD cells compared to 
PAX3/FOXO1 phosphomutants 
All sites found by mass spectrometry to be phosphorylated by PLK1 in vitro were 
tested to see if they have an influence on PAX3/FOXO1 protein stability. For this, RD 
cells were transfected again with 1g of plasmid DNA overnight and then treated with 
10 g/ml CHX or DMSO for 6 hours. Protein was isolated and analyzed by Western 
blot at 0h and 6h. Densitometrical quantification was performed with ImageJ 
software. I corrected for loading and measured the 6h time points relative to the 0h 
time points. Then these values were normalized with P3F wt protein levels for each 
mutant. Relative amounts of residual protein of P3F wt served as a reference value 
(100%). Relative amounts of residual protein of the phosphomutants were compared 
to this reference.  
Samples were distributed on two gels. I included the same samples of P3F wt on 
both gels. I observed huge variations for P3F wt protein levels after 6h CHX 
treatment relative to 0h. On the first blot (Fig. 14A left panel), P3F wt protein levels 
were reduced to about 68%, whereas on the second blot (Fig. 14A right panel) 
amount of protein was only reduced by 12%. It was reasoned that this is because of 
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difficulties to accurately quantify low protein levels. It was again seen that P3F wt 
was less expressed than all phosphomutants with the exception of P3F S30A (Fig. 
14A). This was also an observation that I made in my infection experiments. 
However, in this setting I transfected exactly the same amount of plasmid DNA. This 
suggests that P3F wt is expressed less than P3F phosphomutants in RD cells. CHX 
treatment caused successful degradation of all proteins (Fig. 14A). The extent of 
Cyclin B1 degradation however was not consistent throughout all samples (Fig. 14A). 
On the first blot, where P3F S30A and P3F S389/393A were included, neither of the 
mutants were less stable than P3F wt (Fig. 14B left panel). On the second blot, both 
P3F S399/402A and P3F S503A were apparently less stable than P3F wt (Fig. 14B 
right panel). However, exact quantification of P3F wt was not possible, since too little 
P3F wt protein was loaded. Therefore I could not be completely sure that the effects I 
saw were real. 
 
Figure 14: Testing the stability of PAX3/FOXO1 phosphomutants of sites identified by mass spectrometry 
after in vitro phosphorylation with PLK1 
A) Western blots showing PAX3/FOXO1 wild type and PAX3/FOXO1 phosphomutants protein levels after 
overnight transfection (0h) and 6h cycloheximide treatment (10g/ml) in RD cells. Cyclin B1 protein levels are 
shown for each time point too as an indicator of effective cycloheximide treatment. GAPDH is shown as loading 
control. Densitometrical analysis performed with ImageJ software showing relative protein levels compared to the 
0h time point B) Amounts of residual protein after cycloheximide treatment relative to PAX3/FOXO1 wild type 
residual protein levels  
Results  58 
 
Polo-like kinase 1 mediated phosphorylation regulates PAX3/FOXO1 in alveolar rhabdomyosarcoma 
4.6 Validating the stability of PAX3/FOXO1 phosphomutants by 
CHX treatment of transfected RD cells 
Because of the findings described above, I decided to repeat the experiment with the 
same conditions but loading higher volumes of P3F wt and P3F S30A samples in 
order to have similar amounts of protein to compare. Additionally I wanted to load all 
samples on a single gel. Therefore I excluded all DMSO samples. The two time 
points for the samples were loaded next to each other for further clarification. 
 
Figure 15: Testing the stability of PAX3/FOXO1 phosphomutants of sites identified by mass spectrometry 
after in vitro phosphorylation with PLK1  
A) Western blot showing PAX3/FOXO1 wild type and PAX3/FOXO1 phosphomutants protein levels after 
overnight transfection (0h) and 6h cycloheximide treatment (10g/ml) in RD cells. Cyclin B1 protein levels are 
shown for each time point too as an indicator of effective cycloheximide treatment. GAPDH is shown as loading 
control. Densitometrical analysis performed with ImageJ software showing relative protein levels compared to the 
0h time point B) Amounts of residual protein after cycloheximide treatment relative to PAX3/FOXO1 wild type 
residual protein levels; technical replicates with same samples of one experiment. Error bars represent standard 
deviations  
 
In contrast to previous experiments, by adjusting the sample volumes, I was able to 
see similar amounts of P3F wt and P3F phosphomutants for the 0h time points (Fig. 
15A). This made it less difficult to accurately quantify how much protein was 
degraded after 6 hours of CHX treatment. Also degradation of Cyclin B1 was more 
consistent throughout all samples, suggesting equal effectiveness of CHX treatment 
(Fig. 15A). I determined that P3F wt levels were reduced by 56% after treatment. 
P3F S389/393A and P3F S399/402A protein amounts were reduced by almost 
exactly the same percentage. P3F S30A was not degraded as strongly (47% 
reduction of protein level). However, the only phosphomutant with significantly 
stronger reduction of protein levels after 6 hours of CHX treatment was P3F S503A, 
which was degraded by 75% (Fig. 15A). This suggests that this mutant indeed might 
be less stable than P3F wt. To confirm that this result did not depend on loading or 
blotting procedures, I loaded the same samples with higher volumes a second time. 
Again P3F S503A was the only mutant with a higher level of degradation than P3F wt 
(Fig. 15B). In general, values of protein levels after quantification with ImageJ 
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software were differing only for P3F S30A and P3F S389/393A by about 10%. All the 
other values were nearly identical with the previous values. Taken together, these 
results indicated that the P3F S503A phosphomutant might be less stable than P3F 
wt. Hence phosphorylation of P3F by PLK1 could influence protein stability through 
the cell cycle.  
4.6.1 PAX3/FOXO1 6xA might display reduced stability but needs further 
investigation 
A site within PAX3/FOXO1, which was predicted to be phosphorylated by PLK1 in 
silico, is S510. Interestingly, literature research revealed that PLK1 phosphorylates 
MYC at a site that shows high sequence homology to S510 in PAX3/FOXO1. By this 
phosphorylation event, ubiquitinylation and degradation of MYC is reduced and 
therefore gets stabilized [56, 57]. Because of this I wanted to test the P3F S510A 
phosphomutant in regard to protein stability. The mutant was generated by site 
directed mutagenesis as described before. A second mutant I wanted to test was 
P3F 6xA, because I saw that protein levels differed compared to P3F wt after 
retroviral transduction of RD cells despite equal expression on mRNA level (see 
section 4.3.4). The same protocol as before was used (see sections 4.4 - 4.6). 
However, the data presented below are preliminary, since I only repeated the 
experiment once. 
 
Figure 16: PAX3/FOXO1 S510A and 6xA display no differences in stability compared to PAX3/FOXO1 wild 
type (Preliminary data)  
RD cells were transfected with PAX3/FOXO1 wild type and PAX3/FOXO1 phosphomutants and treated with 
10g/ml cycloheximide for 6h A) Western blot showing relative amounts of residual PAX3/FOXO1 wilt type and 
PAX3/FOXO1 S510A and 6xA proteins. Protein levels are relative to PAX3/FOXO1 wild type B) Western blot 
showing relative amounts of residual PAX3/FOXO1 wilt type and PAX3/FOXO1 S510Aand 6xA proteins. Protein 
levels are relative to PAX3/FOXO1 wild type. Biological replicates of two independent experiments. Error bars 
represent standard deviations 
 
In a first experiment, P3F 6xA was almost twice as strongly degraded as P3F wt (Fig. 
16A). However, this was not reproducible in a second experiment, where P3F 6xA 
was again almost equally degraded as P3F wt (101%). For P3F S510A, I could 
determine that the protein was degraded to almost the same level as P3F wt in two 
independent experiments (80% and 94%) (Fig. 16 A/B). So far I can conclude that 
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probably P3F S510A is not less stable than P3F wt. As far as P3F 6xA is concerned, 
further experiments have to be done to allow definite conclusions. 
4.6.2 PAX3/FOXO1 S503A displays decreased protein stability compared to 
PAX3/FOXO1 wild type 
Finally, biological triplicates were generated using the same protocol as mentioned 
above (see sections 4.4 - 4.6). I was able to reproduce that P3F S503A protein levels 
were more decreased than those of P3F wt after 6h treatment with 10 g/ml CHX. 
Hence, I could demonstrate that P3F S503A has a significantly lower stability 
compared to P3F wt (Fig. 17A). On average, protein levels of P3F S503 were 47% 
stronger reduced than those of P3F wt. All other P3F phosphomutants of sites 
identified to be phosphorylated in vitro by PLK1 showed no significant difference in 
protein stability after 6h treatment with 10 g/ml CHX (Fig. 17B).  
 
Figure 17: The PAX3/FOXO1 S503A phosphomutant displays lower stability upon cycloheximide 
treatment in RD cells 
Biological replicates of three independent experiments; RD cells were transfected with PAX3/FOXO1 wild type 
and PAX3/FOXO1 phosphomutants and treated with 10g/ml cycloheximide for 6h A) Western blot showing 
relative amounts of residual PAX3/FOXO1 wilt type and PAX3/FOXO1 S503A proteins. Protein levels are relative 
to PAX3/FOXO1 wild type. p=0.0052 (unpaired t-test) B) Western blot showing relative amounts of residual 
PAX3/FOXO1 wilt type and PAX3/FOXO1 S30A, S389/393A and S399/402A proteins. Protein levels are relative 
to PAX3/FOXO1 wild type. No significant differences were detected (unpaired t-test) 
 
In conclusion, I could identify a novel site of phosphorylation at S503 in 
PAX3/FOXO1. In addition, further experiments suggest that this phosphorylation 
event contributes to PAX3/FOXO1 stabilization and thereby enhances its 
transcriptional activity. Since PLK1 is specifically active during the G2/M phase of the 
cell cycle, stabilization of PAX3/FOXO1 might contribute to cell cycle progression.
Discussion  61 
 
Polo-like kinase 1 mediated phosphorylation regulates PAX3/FOXO1 in alveolar rhabdomyosarcoma 
5 DISCUSSION 
Oncogenic fusion proteins, like the PAX3/FOXO1 chimeric transcription factor in 
aRMS, represent an attractive therapeutic target, because their expression is limited 
to tumor cells. Most importantly, it is suggested that also the tumorigenic driving force 
in aRMS is PAX3/FOXO1 itself. Because aRMS is clinically more aggressive than 
eRMS, and the PAX3/FOXO1 fusion status confers the worst prognosis, novel 
therapies targeting PAX3/FOXO1 are needed. The fact that metastasizing aRMS 
tumors become resistant to conventional chemotherapy and radiotherapy and are 
almost always fatal is another reason to investigate new possibilities for therapy. 
Since it is not possible to inhibit transcription factors directly by small molecules, 
other strategies to indirectly inhibit PAX3/FOXO1 are urgently needed. Interfering 
with posttranslational modifications of PAX3/FOXO1, which play a role in regulating 
its transcriptional activity, may therefore be a useful strategy. Phosphorylation is 
known to regulate the activity of most transcription factors in the human genome by 
several mechanisms. These mechanisms include changes in subcellular localization, 
protein stability, DNA binding ability or protein-protein interactions. Indeed it was 
shown that also PAX3/FOXO1 transcriptional activity is regulated by phosphorylation 
events [46, 61-63]. This indicates that interfering with upstream regulating kinases is 
a promising approach for new molecular therapies. In order to find kinases able to 
regulate PAX3/FOXO1 activity, a RNAi screen of the human kinome and a screen 
with a kinase inhibitor library was performed in aRMS cells with an AP2beta 
luciferase reporter construct. PLK1 was one of the top hits and was further shown to 
interact with PAX3/FOXO1, to regulate its transcriptional activity and also its stability. 
An independent study identified PLK1 through a siRNA library screen against human 
kinases to reduce growth and increase apoptosis in RMS cell lines but not normal 
muscle cells [66]. These findings suggest that PLK1 might be a promising novel 
therapeutic target in aRMS. 
After validating that PLK1 indeed regulates the transcriptional activity of 
PAX3/FOXO1, the aim of this thesis was to identify potential PLK1 phosphorylation 
sites within PAX3/FOXO1. Further I investigated if phosphorylation at any of the 
identified sites influences transcriptional activity of PAX3/FOXO1. Moreover, I wanted 
to know if any of the phosphorylation sites has an influence on PAX3/FOXO1 protein 
stability. 
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5.1 Downregulation of PLK1 decreases transcriptional activity of 
PAX3/FOXO1 by induction of degradation 
In previous experiments, downregulation of PAX3/FOXO1 target gene expression 
was observed after knockdown of PLK1 in aRMS cell lines. Under mild knockdown 
conditions, no degradation of PAX3/FOXO1 nor cell cycle arrest was observed. 
However, if treated with higher concentrations of siRNA both degradation of 
PAX3/FOXO1 and cell cycle arrest were induced. Also other studies indicate that a 
common effect of PLK1 knockdown is cell cycle arrest [66, 72, 73]. This is not 
surprising considering the roles of PLK1 in mitotic progression. We validated the 
reduction of target gene expression in RMS13 cells using a second siRNA. Again, we 
induced degradation of PAX3/FOXO1 protein after siRNA treatment. Also, a strong 
G2/M arrest was observed. These findings were made with lower siRNA 
concentrations compared to experiments with the first siRNA. Because s449 siRNA 
is a second generation product, it is supposed to be more potent.  
Together these results indicate that PLK1 is able to regulate the transcriptional 
activity of PAX3/FOXO1. Most probably, this effect is mediated by direct 
phosphorylation of PAX3/FOXO1 by PLK1 because both were shown to interact with 
each other. We therefore suggest a mechanism by which PAX3/FOXO1 is stabilized 
upon phosphorylation by PLK1. However, degradation could additionally be indirectly 
caused by cell cycle arrest. Later experiments of Verena Thalhammer showed 
degradation of PAX3/FOXO1 upon treatment of cells with vincristine or colchicine, 
which also induce mitotic arrest. Besides influencing the stability of PAX3/FOXO1, 
other effects of PLK1 mediated phosphorylation are likely because target gene 
expression was also reduced without degradation of the protein, as observed in 
knockdown experiments with s1341. Since we did never observe the same in 
experiments with s449 siRNA, also an off target effect of the first siRNA cannot be 
excluded. 
5.2 PLK1 phosphorylates PAX3/FOXO1 in vitro 
To better understand the underlying molecular mechanisms, by which PLK1 
regulates the activity of PAX3/FOXO1, it is crucial to characterize the sites of 
phosphorylation within PAX3/FOXO1 for PLK1. To investigate this, we 
phosphorylated PAX3/FOXO1 in vitro and detected the phosphorylation sites using 
mass spectrometry.  
We found several different peptides to be phosphorylated by PLK1 in vitro. Because 
of technical obstacles, it was not possible to define the exact site of phosphorylation 
within single peptides. However, we investigated six potential PLK1 phosphorylation 
sites, which might have an influence on PAX3/FOXO1 activity. We further had some 
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problems including incomplete dephosphorylation after CIP treatment. Unfortunately, 
we were so far not able to purify PAX3/FOXO1 from bacteria, which probably would 
have been an advantage in this regard. Also some sequences of PAX3/FOXO1 were 
not covered. To cover sequences previously uncovered, I suggest digestion of 
samples with additional endoproteinases in future experiments. Therefore, we think 
that there could be more potential PLK1 phosphorylation sites in PAX3/FOXO1. It is 
also not completely sure that the identified sites within PAX3/FOXO1 are also 
phosphorylated by PLK1 in vivo. The reason for this is that sometimes in vitro 
phosphorylation can be unspecific. Besides the identification of phosphorylation by 
mass spectrometry, we were also able to identify in vitro phosphorylation of S503 
with a phosphospecific antibody by Western blot analysis, since phosphorylation at 
this site in FOXO1 (S322) is already described. Together these findings indicate that 
S503 is a phosphorylation site in PAX3/FOXO1 for PLK1. Using the same antibody to 
demonstrate in vivo phosphorylation at this site will be an important step in future 
experiments. In previous experiments, the peptide containing S503 was found 
phosphorylated by mass spectrometry if PAX3/FOXO1 was purified from RMS13 
cells. 
5.3 Phosphorylation of PAX3/FOXO1 at S503 by PLK1 has a 
stabilizing effect  
Studies in differentiating mouse myoblasts revealed that PAX3/FOXO1 is more 
stable than PAX3 and persists throughout myogenic differentiation, which may lead 
to the inability to terminally differentiate. It was reasoned that this is caused by 
posttranslational stabilization of PAX3/FOXO1 [85]. Phosphorylation can increase the 
stability of proteins by several mechanisms. One of which is the inhibition of E3 
ubiquitin ligase substrate recognition [86]. Such an effect was already described for 
MYC, which is stabilized by PLK1 mediated phosphorylation [56, 57]. A recently 
published study also found that treatment of aRMS cells with thapsigargin, which 
activates AKT, inhibits PAX3/FOXO1 activity by phosphorylation. Thapsigargin 
inhibited the binding of PAX3/FOXO1 to target genes and promoted its proteasomal 
degradation [63]. Together this shows that phosphorylation by PLK1 can have a 
stabilizing effect and that phosphorylation of PAX3/FOXO1 can influence its stability. 
Site directed mutagenesis of sites that are potentially phosphorylated by kinases is a 
useful strategy to determine the functional effect of phosphorylation at this site on the 
protein. With this in mind, I transformed the sites identified to be phosphorylated in 
vitro by PLK1 into alanine. These sites can therefore no longer be phosphorylated. 
Because we assumed that PLK1 mediated phosphorylation also stabilizes 
PAX3/FOXO1, as knockdown experiments suggested, I investigated the stability of 
phospomutants of sites identified after in vitro phosphorylation by PLK1. I did this by 
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transfecting RD cells with P3F wt or P3F phosphomutants followed by cycloheximide 
treatment for 6 hours.  
I was able to identify one phosphomutant with reduced stability compared to P3F wt. 
This mutant was PAX3/FOXO1 S503A. This result indicates that phosphorylation of 
PAX3/FOXO1 at S503 by PLK1 stabilizes the protein. This leads me to the 
assumption that PAX3/FOXO1 can act more efficiently as a transcriptional regulator 
due to this stabilization event. This induces enhanced expression of PAX3/FOXO1 
target genes with high tumorigenic capacity and finally contributes to malignant 
transformation. Thus, intervening with PLK1 function using small molecule inhibitors 
is an excellent strategy, also because PLK1 is overexpressed in RMS tumors (Fig. 
18).  
 
Figure 18: Working hypothesis for the regulation of PAX3/FOXO1 by PLK1 mediated phosporylation at 
S503 in aRMS cells 
 
This working hypothesis provides a molecular mechanism for the deeper 
understanding of how PLK1 regulates PAX3/FOXO1 and reinforces the 
establishment of PLK1 as a novel therapeutic target in aRMS. However, further 
experiments have to be performed for validation.  
A first important experiment would be to mutate S503 into aspartic acid. This 
mutation should mimic phosphorylation and therefore lead to a rescue of 
PAX3/FOXO1 degradation in CHX experiments. The same could also be tested in 
pulse-chase experiments with higher accuracy. A particular advantage of pulse 
chase experiments over CHX treatements is that it provides minimal distortion of 
normal cell physiology. To prove that S503A can no longer be phosphorylated by 
PLK1, an in vitro phosporylation with PLK1 with this mutant should be performed. No 
band on Western blot should be detected with anti-FOXO1 (pS322) antibody. A 
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particularly important experiment would be to treat aRMS cells with PLK1 inhibitors 
and check with anti-FOXO1 (p322) antibody if phosphorylation of endogenous 
PAX3/FOXO1 at this site still occurs.  
If my findings can be validated by these means, further investigations in order to 
reveal the mechanistic background of how PAX3/FOXO1 stabilization is achieved 
should be made.  
A possibility would be that the phosphorylation event on S503A of PAX3/FOXO1 by 
PLK1 interferes with binding to an E3 ligase, which ubiquitinates it and targets it for 
proteasomal degradation. This assuption is partly supported by previous experiments 
in which a rescue of degradation of P3F wt was observed after PLK1 inhibition and 
treatment with proteasomal inhibitor (bortezomib) in aRMS cells. If a rescue can be 
found in experiments where P3F S503A transfected cells are treated with CHX and 
proteasomal inhibitor, it would strengthen this hypothesis. In order to find which E3 
ligase might be associated, co-immunoprecipitation experiments could be performed. 
E3 ligases, which pull down with P3F S503A but not P3F S503D would be interesting 
candidates. Alternatively, a siRNA screening against E3 ligases is another possible 
approach. Knockdown of associated E3 ligases should lead to a rescue in 
degradation of P3F S503A. However, association with E3 ligases is not the only 
mean by which phosphorylation can affect protein stability. Theoretically, 
phosphorylation can affect the structure of a protein and directly alter its 
thermodynamic stability.  
5.4 PLK1 is a promising therapeutic target especially for aRMS 
Consistent with its role in promoting proliferation, chromosome instability and 
aneuploidy, PLK1 overexpression has been observed in many cancers and in some 
tumor types even correlates with worse prognosis [72, 75]. By immunohistochemical 
stainings of tissue micro arrays, PLK1 overexpression also was found to confer 
poorer prognosis in aRMS [65]. Numerous studies with siRNA or small molecule 
mediated PLK1 inhibition indicated that cancer cells undergo mitotic arrest, 
proliferation inhibition and apoptosis [72, 73, 87-89]. Importantly, PLK1 inhibition was 
shown to preferentially kill cancer cells compared with normal cells [66, 88], which 
provides a potential therapeutic window. In vivo studies with BI2536 PLK1 inhibitor 
additionally showed reduced tumor growth and even regression [65, 90] All these 
findings indicate that PLK1 is a promising cancer target and several clinical trials with 
PLK1 inhibitors have been made [77]. However, genetic evidence of PLK1 being an 
oncogene is not very strong [75].  
In contrast to studies in other cancer types, my work provides evidence for a cancer 
specific mechanism by which PLK1 inhibition mediates an antitumorigenic effect. 
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One could argue that PLK1 overexpression is just a feature of fast proliferating 
cancer cells and does not contribute to tumorigenesis. However, my work suggests 
that PLK1 exerts a direct tumor supporting effect in aRMS by stabilizing 
PAX3/FOXO1 via phosphorylation, which might contribute to cell cycle progression. 
Because aRMS cells depend on the constitutive expression of PAX3/FOXO1, 
apoptosis upon PLK1 inhibitor treatment might be induced by degradation of 
PAX3/FOXO1.  
My results, if they can be validated, strongly suggest that PLK1 is a suitable 
therapeutic target especially in aRMS, because of its potency to stabilize 
PAX3/FOXO1 by direct phosphorylation. This argues for increased inclusion of 
aRMS patients in clinical trials with PLK1 inhibitors. Especially aRMS patients with 
PLK1 overexpression could benefit from such treatment. Of course there are 
difficulties to recrute enough patients since aRMS is a very rare disease. Additionally 
children are difficult to include for clinical trials. Because PLK1 is additionally involved 
in stabilization of the MYC oncogene, which is currently undruggable, MYC 
overexpressing tumors could also benefit from PLK1 inhibitors. Since MYC plays an 
important role in promotion of many human cancers, PLK1 inhibitors might be 
applicable to a broad range of cancers other than aRMS. 
5.5 Retroviral transduction of RD and hMSC cells as a potential 
tool for testing PAX3/FOXO1 phosphomutants 
To test phosphomutants in regard of transcriptional activity, I needed to develop a 
new read-out system. Delivery of genetic material using retroviruses is a commonly 
used method to stably express genes of interest in target cells. Previous experiments 
of Verena Thalhammer indicated that stable expression of PAX3/FOXO1 is 
necessary to induce target gene expression. It was shown that upon transduction of 
RD cells with PAX3/FOXO1, an expression profile was induced that resembled the 
expression signature of aRMS cell lines [80]. Another study showed that mMSC cells 
transduced with PAX3/FOXO1 and SV40-LT induced tumors in mice, which 
expressed aRMS specific genes [81].  
Regarding these findings, I tried to induce PAX3/FOXO1 target gene expression by 
retroviral transduction of different cell lines. The purpose was to find a cell line in 
which I could test the activity of PAX3/FOXO1 phosphomutants compared to 
PAX3/FOXO1 wild type. I was able to show that transduction of RD cells with 
PAX3/FOXO1 induces target gene expression. But no target gene expression was 
induced in mMSC cells. A possible explanation for this might be that cooperating 
secondary mutations and/or correct in vivo cellular background are needed in 
addition. Also other cell lines showed PAX3/FOXO1 target gene expression after 
transduction but were less suitable for the testing of PAX3/FOXO1 phosphomutants. 
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Primary hMSCs for example were difficult to infect. Additionally, this cell line grows 
very slowly in culture. However, the infection efficiency might improve if virus 
supernatant would be concentrated before infecting the cells. Additionally, the effect 
on PAX3/FOXO1 target genes was quite strong and also genes that were previously 
not expressed could be induced. This is why this cell line is still an alternative to try 
for testing of phosphomutants. Anyway, the best system for this purpose would be to 
knock down endogenous PAX3/FOXO1 in aRMS cell lines with shRNA directed 
against the 3’UTR and subsequently transduce these cells with PAX3/FOXO1 
phosphomutants. This is currently being established in our laboratory. 
I was able to show that in principal, testing of transcriptional activity of PAX3/FOXO1 
phosphomutants is possible using retroviral transduction of RD cells. This 
assumption is based on the fact that transduction with positive controls (DNA binding 
mutants and the 6xA phosphomutant of PAX3/FOXO1) led to a weaker induction of 
target genes compared to transduction with PAX3/FOXO1 wild type. However, I 
could not identify a PAX3/FOXO1 mutant of sites phosphorylated by PLK1 in vitro 
with reduced transcriptional activity. In my experiments, target gene expression was 
stronger in cells transduced with PAX3/FOXO1 phosphomutants compared to 
PAX3/FOXO1 wild type. Most probably, this is because I did not titrate virus 
supernatants and transduction was more efficient with PAX3/FOXO1 
phosphomutants compared to PAX3/FOXO1 wild type. This indicates that for the 
correct testing of PAX3/FOXO1 phosphomutants in this setting, it is crucial to have 
same infection efficiencies compared to PAX3/FOXO1 wild type, in order to be able 
to accurately compare transcriptional activities. Therefore I strongly suggest 
calculating viral titers of all viral stocks and transduce cells with same amounts of 
viral particles, to improve the retroviral system for testing the activity of PAX3/FOXO1 
phosphomutants.  
Determination of viral titer using flow cytometry allows calculating the number of 
actual viable transducing viral particles present in the viral stock. Since my retroviral 
plasmid codes for the GFP reporter gene, this would be the method of choice. Other 
techniques like qRT-PCR assay simply determine how many particles are present 
but do not consider how many of those particles are viable and also capable of 
infection. I suggest to directly titrate viruses on cells that will have to be infected later. 
In my case these would be RD or also primary hMSC cells. Virus can be produced in 
the same way as successfully done previously. Additionally, I would concentrate virus 
supernatant for later infection of primary hMSC cells. Because the VSV-G 
glycoprotein of virus produced with 293 GPG cells adds physical stability to retroviral 
particles, they are suitable for concentration by high-speed ultracentrifugation. 
Afterwards, serial dilutions of virus stock should be made. The goal of this is to reach 
transduction in the range of 1-20% GFP positive cells. Above this range, chances 
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that GFP positive cells were infected more than once is very likely. This would lead to 
an underestimation of viral titer [91]. Infection of target cells with dilutions of viral 
stock can be performed as described. 72 hours post infection, the percentage of GFP 
positive cells for each infection condition can be estimated by FACS as described. In 
the condition resulting in 1-20% GFP positive cells, the titer of transducing units per 
ml (TU/ml) can be calculated by dividing the number of transduced cells, assuming a 
doubling 24 hours after plating, by the volume of viral stock used. This should be 
done for viral stocks of PAX3/FOXO1 wild type virus and PAX3/FOXO1 
phosphomutants viruses. MOI (multiplicity of infection) is the ratio of transducing 
units present per cell. Using a specific MOI allows prediction of how many particles 
will transduce one cell. Same MOIs should be used to transduce cells with 
PAX3/FOXO1 wild type and PAX3/FOXO1 phosphomutants. This ensures that the 
same percentage of cells get infected with same amounts of viral particles per cell. 
To determine the optimal MOI for this assay, I would use a range of MOIs in a first 
experiment.  
The differences observed in transduction efficiencies between PAX3/FOXO1 wild 
type and PAX3/FOXO1 phosphomutants in my experiments indicate two things. First, 
more cells are transduced with PAX3/FOXO1 phosphomutants compared to 
PAX3/FOXO1 wild type. Second, they probably also contain more copies per cell 
than cells transduced with PAX3/FOXO1 wild type. Consequently, they are also 
higher expressed on mRNA level and also induce PAX3/FOXO1 target gene 
expression more strongly. Thus, even if a mutation might have an effect on 
PAX3/FOXO1 transcriptional activity, no difference can be observed, simply because 
more protein is present. Another problem is that, at least with RD cells, PAX3/FOXO1 
wild type seems to be less expressed than PAX3/FOXO1 phosphomutants. If this is 
an effect only observed after short periods of transient transfection remains to be 
seen. Although I cannot predict if I can expect to see differences in target gene 
expression with titrated virus supernatants, it is an important step for evaluating the 
quality of the read-out system. If, using same MOIs for transduction of cells, target 
gene expression should be weaker in P3F 6xA (already observed), P3F 4xA and P3F 
5xA (not investigated yet) transduced cells compared to P3F wt transduced cells, this 
would be a sign of good quality and high sensitivity. If so, I would also expect to see 
less target gene expression with the P3F S503A phosphomutant (considering the 
working hypothesis). However, an effect resulting from reduced stability of this 
mutant might get masked on target gene level because of constitutive expression of 
the mutant in this system. Consequently, compensation for degraded protein 
happens. A possible alternative could be to test target gene expression compared to 
P3F wt after exposure to CHX. Since other mechanisms than PAX3/FOXO1 protein 
stabilization are potentially induced by PLK1 mediated phosphorylation, other 
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phosphomutants might affect transcriptional activity. If single alanine mutants should 
not lead to a decrease of target gene expression, I would suggest mutating whole 
clusters of potential phosphorylation sites.  
5.6 Synopsis 
In conclusion, I was able to validate that downregulation of PLK1 leads to decreased 
transcriptional activity of PAX3/FOXO1 in aRMS cell lines. Additionally I identified 
sites within PAX3/FOXO1, which are potentially phosphorylated by PLK1 in vitro. My 
findings of cycloheximide treatments suggest that phosphorylation of PAX3/FOXO1 
at S503 has a stabilizing function. These results provide a mechanism for the 
regulation of PAX3/FOXO1 through phosphorylation by PLK1. This reinforces the 
establishment of PLK1 as a novel target for the treatment of aRMS. Additionally, 
retroviral transduction of RD and also primary hMSC cells may be a useful tool for 
the identification of phosphosites with an influence on PAX3/FOXO1 transcriptional 
activity.
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